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2. Abbreviations and definitions 
ACS    Acute Coronary Syndrome 
AED   Automated External Defibrillator  
AF   Atrial fibrillation 
ATP   Adenosine triphosphate  
BMI   Body mass index 
BNP   B-type natriuretic peptide  
CAC   Coronary artery calcium 
CAD   Coronary artery Disease 
CCTA  Coronary Computed Tomography Angiography 
CI   Confidence interval  
CK   Creatine kinase 
CK-MB  Creatine kinase – myocardial band  
CMR   Cardiac magnetic resonance imaging  
CO2   Carbon dioxide  
CRP   C-reactive protein 
cTn   Cardiac troponin 
cTnI   Cardiac troponin I 
cTnT   Cardiac troponin T 
CV   Cardiovascular 
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ECG   Electrocardiogram  
EDTA   Ethylenediaminetetraacetic acid  
ESC   European Society of Cardiology  
fsTnI   Fast skeletal muscle troponin I 
Half-marathon 21 kilometre running event 
HR   Hazard ratio 
HDL   High-density lipoprotein 
IPAQ   International Physical Activity Questionnaire  
LAD   Left anterior descending artery 
LDL   Low-density lipoprotein  
LGE   Late gadolinium enhancement  
Marathon  42 kilometre running event 
MET   Metabolic equivalent of task 
NA   Not available  
NEEDED   The North Sea Race Endurance Exercise Study 
NT-proBNP  N terminal pro Brain Natriuretic Peptide 
REK   Regional Ethic Committee  
SCA   Sudden Cardiac Arrest 
SCD   Sudden Cardiac Death 
SCORE  Systematic Coronary Evaluation 
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ssTnI   Slow skeletal muscle troponin I 
WHO   World Health Organization 
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Physical exercise induces changes in cardiac biomarkers associated with cardiac 
injury and inflammation. The ability of these changes to identify subjects at risk of 
sport-related cardiac events is largely unknown. This project aimed to identify the 
physiological pattern and predictors of the exercise-induced cardiac troponin (cTn) 
and C-reactive protein (CRP) response to exercise. A potential pathological response 
to exercise was explored in a subset of subjects.  
Methods 
The exercise-induced increase in cTn and CRP were studied in two cohorts of 
presumably healthy recreational athletes; The North Sea Race Endurance Exercise 
Study (NEEDED) 2013 (n=97) and 2014 (n=1002). Both studies obtained data before 
and within 24 hours after a 91-kilometre cycling competition (“The North Sea 
Race”). Coronary computed tomography angiography was used in a subset of 
subjects to identify a possible association between exercise-induced cTn elevation 
and underlying coronary artery disease.  
Results 
In Paper 1 (n=97), we determined the magnitude and time-dependent changes in cTnI 
following the North Sea Race. There was a continued increase in cTnI between 
immediately after the race and 3 hours following the race. This finding was important 
for the design of the main study. Also, three of the four subjects with highest 
exercise-induced cTnI values had significant coronary artery pathology.  
In Paper 2 (n=1002), 84-92 % of subjects exceeded the 99th percentile of the cTn 
assay 3 hours post-race. At 24 hours post-race, 18-30 % still had cTn values above 
the 99th percentile. Lower race duration and higher systolic blood pressure were 
predictors of the exercise-induced cTn increase.  
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In Paper 3 (n=120), subjects were assessed by coronary computed tomography 
angiography (CCTA). Subjects with obstructive CAD (n=9) had significantly higher 
cTn levels at 24 hours after the race, but not at 3 hours after the race.  
In paper 4 (n=97), the CRP response to exercise was determined. In this study, CRP 
continued to increase until 24 hours following the race. Physical fitness was found to 
significantly attenuate the exercise-induced CRP response. There was no association 
between exercise-induced levels of CRP and cTnI.   
Conclusion 
The present work identified the physiological pattern and predictors of exercise-
induced cTn and CRP. More than 84 % of subjects had cTn levels above the 99th 
percentile cut-off. This finding supports the hypothesis that exercise-induced cTn 
increase is a physiological response in most subjects. Lower race duration and higher 
systolic blood pressure were consistent predictors of the exercise-induced cTn 
response. In a subset of subjects, a prolonged elevation of cTn was associated with 
occult obstructive CAD, suggesting a pathological pattern of cTn increase in these 
subjects. Lastly, physical fitness was inversely associated with the exercise-induced 
CRP response. No association between exercise-induced cTn- and CRP increase was 
identified.   
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5. Introduction  
The World Health Organization (WHO) has identified physical inactivity to be the 
fourth leading risk factor of global mortality, only surpassed by high blood pressure, 
tobacco use and high blood glucose (1). Regular physical activity reduces all-cause 
and cardiovascular (CV) mortality by 20-39 % as compared to a sedentary life style 
(2). Increasing physical activity among the general population is therefore an 
attractive avenue for public health initiatives.  
Adherence to regular physical activity is a considerable challenge. In a Norwegian 
study, only 32 % of adults fulfilled the current recommendations on weekly physical 
activity (3). Participation in recreational endurance exercise competitions such as 
marathons, ultra-marathons and cycling competitions serves as important 
motivational factors to uphold regular physical activity (4). The effect of vigorous 
exercise on the cardiovascular (CV) system, however, is not completely understood. 
In particular, sport-related cardiac events occur rarely, but regularly, and have 
potential catastrophic ramifications for those who are affected.   
The European Sport Cardiology group recommends all athletes to undergo a pre-
participation evaluation with a medical history and a resting 12-lead 
electrocardiogram (ECG) in order to minimize the risk of sport-related cardiac events 
(5). For athletes > 35 years of age, the main cause of sport-related cardiac events is 
coronary artery disease (CAD), and most victims of sport-related cardiac events are 
asymptomatic prior to the event (6-8). As such, these subjects are difficult to identify 
within the current evaluation algorithm. Research into novel strategies to identify 
subjects at-risk of sport-related cardiac events is therefore indicated.   
Multiple studies have demonstrated significant increases in cardiac biomarkers 
following strenuous physical activity, with levels of cardiac markers increasing 
beyond the cut-off values of myocardial injury. The ability of these biomarkers to 
identify subjects who are potentially at risk of sport-related cardiac events is largely 
unknown. In this project, the physiological and potential pathological pattern of 
exercise-induced cardiac troponin (cTn) and C-reactive protein (CRP) are assessed.  
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5.1 Health benefits of regular physical exercise 
There is strong evidence that regular physical exercise lowers all-cause mortality, 
coronary heart disease, high blood pressure, stroke, metabolic syndrome, type 2 
diabetes mellitus, breast cancer, colon cancer, depression and falling (9). It also 
promotes higher level of cardiorespiratory and muscular fitness, enhanced bone 
health, better cognitive function and a healthier body mass and composition (9).  
5.1.1 Physical inactivity  
Physical inactivity is defined as a failure to meet 
the WHO recommendations on weekly physical 
activity (Figure 1) (9,10). In a global perspective, 
31.1 % of adults are physically inactive (11).  
In 2008, physical inactivity contributed to more 
than 5.3 million deaths worldwide (10). This 
corresponded to 9 % of premature mortality, and 
was a risk factor that contributed similarly to poor 
health as smoking and obesity. Inactive subjects are 
estimated to have a 16 % higher relative risk of 
incident coronary heart disease when compared to 
active subjects (10). The estimated relative risk increase for incident type 2 diabetes 
mellitus is 20 %, for breast cancer 33 %, colon cancer 38 % and all-cause mortality 
28 % (10).  
In a Norwegian cohort study conducted in 2015, only 1 of 3 adults fulfill the WHO 
recommendations for weekly physical activity (3). Social differences influenced the 
results markedly; male subjects who had a higher education were almost twice as 
likely to fulfill the recommendations as compared with male subjects with a primary 
school education only. In total, 62 % of time spent awake was inactive. The most 
common reason for inactivity was reported as “I do not have sufficient time to 
exercise” (37 %) (3).  
WHO recommendation on 
physical activity for adults: 
 
Minimum 150 minutes of 
moderate physical activity, or 
75 minutes of vigorous 
physical activity per week 
 
Muscle-strengthening activities 
on two or more days a week 
Figure 1: WHO 
recommendations 
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5.1.2 Current recommendations for regular physical exercise 
The WHO recommendations on weekly physical activity is outlined in Figure 1. 
Physical activity should be performed in bouts of at least 10 minutes duration, and 
includes activities during leisure-time, transportation and during working hours. 
Muscle strengthening exercises should include major muscle groups on 2 or more 
days a week.  
There is a dose-response relationship with exercise and good health (9,12). As such, 
higher volumes of activity (up to 300 minutes of moderate exercise, or up to 150 
minutes of vigorous exercise per week) is recommended for additional health 
benefits. Evidence of additional health benefits for exercise volumes greater than 300 
minutes of moderate exercise per week is weak (9).  
5.1.3 Challenges and motivation for regular physical activity 
Physical inactivity is multifactorial, and depends on both individual factors such as 
age, sex and socio-economic status, as well as genetic, environmental and 
geopolitical factors (13). High crime rates and dense traffic may be obstacles to 
outdoor physical activities (13). Seasonal variations, as well as the absence of parks 
or recreational areas are also barriers to regular physical activities (3). Individual 
barriers also include limited time to exercise, lack of enjoyment of exercise, reduced 
self-efficacy, low social support, companionship, safety and/or a misconception of, or 
lack of knowledge of the physical activity guidelines (3,13).   
Motives for continuing regular physical activity includes body-oriented motives, 
nature experiences, sociability, mental and physical well-being, stress-reduction and 
long-term positive health effects (14,15). Several studies also mention challenges and 
achievement as important motives for continued physical activity, particularly for 
men (4,14). In the “Running USA 2017 survey” (n=6 800), 62 % answered that 
training for a race was a major motivational factor to continue regular physical 
activity (16).  
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Between 2009-2014 a 13.3 % global increase in marathon participation has been 
reported (17). In line with this, several Norwegian endurance exercise competitions 
experienced considerable growth in this period (Figure 2).  
  
Figure 2: Participation in large Norwegian endurance exercise competitions between 1990-2015 
(%). Grenserittet, Nordsjørittet (The North Sea Race) and Birken are cycling competitions, Oslo 
Marathon represents the largest marathon race in Norway and Birken (ski) is a cross-country skiing 
event. This figure was published by NRK.no 01.08.2017, and permission for reprint has been 
obtained (18).   
5.2 Metabolic equivalents and exercise intensity 
On a scale relative to an individual’s personal capacity, moderate exercise is defined 
as physical activity of 5-6 on a scale to from 0-10, while vigorous exercise is defined 
as 7-8 on the same scale (9). This definition is commonly used in public health 
recommendations, as it is easy to understand and use. In absolute terms, however, 
exercise intensity may be defined as the ratio of the rate of energy expended during 
an activity to the rate of energy expended at rest. At rest, 1 metabolic equivalent of 
task (MET) is 3.5 ml oxygen/kg/min (9). Walking at a pace of 5.3 km/hour requires 
3.3 METs. Running at a pace of 9.7 km/h requires 10 METs. By multiplying the 
METs required by the specific activity by the number of minutes that the activity is 
performed, provides MET minutes. Activities requiring 3-5.9 METs are classified as  
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moderate exercise, while activates requiring ≥ 6 METs are classified as vigorous 
exercise (9). 500-1000 MET minutes per week roughly corresponds to the 
recommendations on weekly physical activity by WHO.   
Example: Walking at a pace of 5.3 km/hours for 1 hour would generate (3.3 MET x 
60 minutes) 198 MET minutes. Running at a pace of 9.7 km/h for 20 minutes would 
generate (10 MET x 20 minutes) 200 MET minutes.   
5.3 Basic exercise physiology 
During rest, cardiac output is approximately 5 L/min, whereof 20 % is directed 
towards the musculature (6). During strenuous physical activity, the heart needs to 
increase its pumping capacity in order to supply oxygen and nutrients to peripheral 
organs. The heart is able to increase its pumping capacity (cardiac output) by 4-8 
times during acute bouts of exercise (25-35 l/min), primarily by increase in heart rate, 
but also due to increased stroke volume and contractility (6,19,20).  
Exercise starts by the brain initiating movement from the motor cortex (6). 
Concomitantly, the sympathetic nervous system is activated (6). The release of 
noradrenaline and adrenaline into the circulation leads to an increase in heart rate and 
widespread vasoconstriction, with the exception of blood flow to the exercising 
muscles and tissues without the ability for substantial vasoconstriction (cerebral and 
cardiac circulation). This increases systolic blood pressure. During exercise, the 
musculature needs about 84 % of the entire blood flow (6). In order to ensure 
adequate blood flow to the muscles, local factors within the muscle cause their blood 
vessels to dilate (6,19).  
Exercise requires chemical energy to be converted into kinetic energy. This is 
achieved by splitting adenosine triphosphate (ATP). ATP is generated from metabolic 
substrates, such as glucose and fatty acids. During aerobic metabolism, one glucose 
molecule yields 36 molecules of ATP (6). This process consumes six oxygen 
molecules and produces six carbon dioxide (CO2) molecules (6). The oxygen cost of 
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using fatty acids to produce ATP is higher, and the rate of energy production is much 
lower.  
Ventilation is central in exercise physiology. Healthy subjects are capable of 
increasing ventilation from 6 L/min at rest to > 100 L/min during strenuous exercise 
(6). In addition, gas exchange is more efficient during exercise, due to increased 
pulmonary capillary perfusion and greater recruitment of alveoli (6). However, under 
anaerobic conditions, energy can still be produced, but the production of energy is far 
more costly. During anaerobic metabolism, one molecule of glucose will only 
produce 3 molecules of ATP (6). Anaerobic energy production also leads to acidosis, 
which needs to be buffered. This in turn leads to an increase in CO2 production, and 
an increased respiratory gas exchange ratio (> 1.0), underscoring the lungs additional 
highly important function in buffering (6).  
Exercise capacity is limited both by the ability to delivery of oxygen to peripheral 
tissues (central factors), and the ability to extract and use oxygen (peripheral factors) 
(6). In order to overcome these limitations, substantial cardiovascular, muscular and 
pulmonary adaptations may occur in athletes. As such, relatively untrained subjects 
will have smaller cardiac dimensions, less developed musculature and vasculature 
and a lower degree of exercise efficiency as compared with highly trained athletes. 
Different levels of exercise-induced adaptations might therefore yield different 
cardiac and peripheral responses to exercise. The association between physical fitness 
and exercise-induced increases in cardiac biomarkers, however, is largely unknown.  
5.4 Long-term cardiovascular adaptations to strenuous 
physical activity 
By engaging in regular physical exercise, adaptations of the heart occur to match the 
increased demands on the cardiovascular system. This may lead to a physiological 
increase in cardiac wall thickness and/or ventricular and atrial sizes; the so called 
“athlete’s heart” (20,21). Cardiac myocytes are terminally differentiated, and as such, 
the increase in cardiac mass is due to increased myocyte size, and not due to an 
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increase in the number of cardiac myocytes (19). Early cardiac adaptations, however, 
also includes adaptive changes within the cardiac myocytes, such as overexpression 
of isoform α of the myosin heavy chain and alterations of the Ca2+ regulatory system 
(6). Increased cardiac vessel size and number have also been described, contributing 
to increased coronary blood flow (6).  
The increased left ventricular cavity in athletic subjects corresponds with an 
increased stroke volume. Left ventricular ejection fraction is usually unaffected by 
this physiological remodelling, but the mechanical systole might be shorter in 
athletes, as compared to controls, underscoring the increased cardiac efficiency in 
trained subjects (6,22). Similarly, right heart chambers might be enlarged, particularly 
among endurance athletes, but systolic function is unchanged (6). A small increase in 
aortic root dimensions might also be seen in athletic subjects (23,24).  
The electrocardiographic changes associated with the athlete’s heart are sinus 
bradycardia, first-degree atrioventricular block, incomplete right bundle branch 
block, early repolarization and isolated QRS voltage criteria for left ventricular 
hypertrophy (25).  
There is ample evidence to support that exercise modality, intensity and duration are 
important factors in the development of exercise-induced cardiovascular adaptations 
(26). A landmark study by Morganroth et al. from 1975 used M-mode 
echocardiography to describe cardiac structure of athletes (27). They found that 
athletes engaged in endurance-type exercises had increased end-diastolic volume and 
mass  (eccentric left ventricular remodelling) as compared to controls, while athletes 
in strength-type sports primarily had increased cardiac mass (concentric remodelling) 
(27). They hypothesized that endurance exercise had similarities with volume 
overload, as seen in aortic or mitral regurgitation, while resistance training was a 
pressure load condition, similar as with aortic stenosis (27). This finding has 
influenced how sport cardiologists have considered cardiac remodelling for decades. 
Newer data derived from contemporary echocardiography and cardiac magnetic 
resonance imaging, however, challenges the notion, with a finding of mostly normal 
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geometry, and with a mix of pressure and volume load both in endurance- and 
resistance-type exercise (26,28,29).     
Cardiac remodelling in athletes is also highly influenced by sex, ethnicity and 
underlying genetic differences (6). Lastly, coronary and peripheral vascular 
adaptations are important as part of this exercise-induced cardiovascular remodelling 
complex, with increased vascular diameters, greater vascular compliance and 
increased capillary density in the trained musculature (6).   
5.5 Risks associated with strenuous physical activity 
Legend states that Pheidippides, a messenger sent to announce victory over the 
Persian army in the year 490 BC, ran from Marathon to Athens, shouted “we have 
won”, and then died. It is said to be the origin story of the Marathon. This story is 
often told to demonstrate the risk involved with performing strenuous physical 
activity. It is, however, likely that this never actually happened, but that it stems from 
a poem by Robert Browning from 1879 (30). However, sudden cardiac death does 
occur occasionally during or shortly after vigorous exercise. These events frequently 
lead to significant media attention, as subjects are often young and healthy. 
Numerous studies have therefore addressed the incidence, cause and prevention 
strategies of sport-related adverse events over the past decades.  
5.5.1 Short-term risks associated with strenuous physical activity 
Injuries in conjunction with strenuous physical activity are common, particularly 
musculoskeletal and dermal/soft tissue injuries (31). For running, 6.8-59 injuries per 
1000 hours of exercise have been reported, with medial tibia stress syndrome, 
Achilles tendinopathy and plantar fasciitis being the most common injuries (32). 
Mountain biking has been associated with 1.52 injuries per 1000 biking sessions, but 
hospital admission for these injuries were rare (5 % of injuries) (33). During half-
marathons (21 km running), 5.15 per 1000 participants suffered a medical 
complication in a prospective 4-year study from South Africa (34). Only 0.51 per 
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1000 participant suffered a serious medical incident, and death occurred in 0.05 per 
1000 participant (n=2) (34).  
The incidence of sport-related sudden death has been reported to be 4.6 cases per 
1.000.000 population per year for the general population of France (35). The incident 
of cardiac arrests during marathons or half-marathons in the United States of America 
has been reported to be 0.54 per 100.000 participants (36). In a retrospective analysis 
of Norwegian sport-related SCDs between 1990-1997, 23 cases were identified (37). 
22 of these deaths occurred in males, and 11 were due to myocardial infarction (37).  
Serious medical adverse events during strenuous exercise may, however, also be due 
to disturbances in fluid and electrolyte regulation, temperature regulation and serious 
injuries. In the South African study of half-marathon running, disturbances in 
fluid/electrolyte/acid-base and temperature regulation were more common than 
serious cardiovascular events (34). Following the Boston Marathon, an incidence of 
hyponatremia of 13 % was identified, however only 0.3 % had critical hyponatremia 
(s-sodium > 120 mmol/L) (38).  
5.5.2 Long-term cardiovascular risks associated with strenuous 
physical activity  
Although moderate exercise reduces the risk of a cardiovascular event from coronary 
artery disease, recent cross-sectional studies have suggested a dose-dependent 
relation between life-long exposure to physical activity and the burden of myocardial 
fibrosis (39-41), coronary artery calcification (39,42,43) and atrial fibrillation in 
highly active subjects (44-47). It is important to note that most of these studies are 
cross-sectional observational studies, and that a causal link between exercise and 
these pathophysiological processes has not been established.   
Myocardial fibrosis  
Several studies have described a high incident of focal myocardial fibrosis in veteran 
athletes. Breuckmann et al. (n=102 male marathon runners 50-72 years of age) found 
that 12 % of marathon runners had late gadolinium enhancement (LGE) on cardiac 
magnetic resonance imaging (CMR), as compared to 4 % of age-matched controls 
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(p=0.08) (41). Merghani et al. found that 14 % of their male athletes had LGE on 
CMR, compared to none of the controls (p=0.004) (39). Wilson et al. found LGE in 6 
(50 %) of their veteran athletes (40). It is important to note that in studies comparing 
veteran athletes with a control group, the study subject characteristics of both groups 
are highly important when comparing results.   
LGE in athletes has been predominantly described in in the interventricular septum 
and at the right ventricular inception point (non-ischemic distributions). For some of 
the athletes with LGE, however, occult CAD or silent myocarditis are suspected as 
the cause (39,48).  
A study in rats performing high-intensity and long duration exercise for 16 weeks 
suggested a higher degree of fibrosis in the exercising rats, as compared to sedentary 
control rats, using histological and biochemical methods (49). These findings have 
not been reproduced in humans, but do suggest that exercise might induce adverse 
remodelling and increased risk of arrhythmias in some individuals.   
Coronary artery disease 
Veteran athletes have also been found to have a surprisingly high prevalence of 
coronary atherosclerosis (Table 1). Braber et al. (n=318) found that 52.5 % of their 
sportsmen had CAC > 0 Agatston Units (50). Möhlenkamp et al. found that 71.3 % of 
their marathon runners (n=108) had coronary artery calcium > 0 Agatston Units, with 
a median CAC of 36 Agatston Units (51). Both of these studies included male 
subjects only, and CV risk factors were prevalent. Aengevaeren et al. (n=284) also 
studied a male cohort of recreational athletes, and found CAC > 0 Agatston Units in 
53 % of subjects and a median CAC of 36 Agatston units. A higher CAC score was 
identified in subjects who reported a higher exercise volume (43). Merghani et al. 
(n=152 athletes, 30 % female) found that 40 % of the total cohort had CAC > 0 
Agatston Units in their athletic cohort (males: 48 %, females: 22 %), and the median 
CAC score in their cohort were 0 Agatston Units (39). Both Aengevaeren et al. and 
Merghani et al. noted that highly active subjects had a higher degree of calcified 
plaques, as compared to less active/control subjects, suggesting a more stable form of 
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CAD (39,43). Similar findings are reported in smaller studies (52,53), except for a 
small study of female subjects, where female marathon runners had lower CAC than 
sedentary female controls (54).  
Table 1: Summary of previous studies on recreational/veteran athletes and coronary artery disease. 
NA = not available.  
 n Females Mean age 
Control 
group 









Möhlenkamp et al. 
2008 




Schwartz et al.  
2014 
50 0 % 59.4±6.7 Yes, with 
more CV risk 
NA NA NA 
Tsifikas et al.  
2015 
50 0 % 52.7±5.9 No 48.0 % Mean: 
44±121 
2.0 % 
Braber et al.  
2016 
318 0 % 54.7±6.3 No 52.5 % NA 5.3 % 
Merghani et al.  
2017 
152 30 % 54.4±8.5 Yes 40.0 % Median: 
0 
5.3 % 
Aengevaeren et al. 
2017 
284 0 % 55.0±6.5 Compared 
different 
activity levels 




Roberts et al.  
2017 
26 100 % 56±10 Yes, with 
more CV risk 
19.2 % NA NA 
DeFina et al. 
2019 






† CAC > 0 Agatston Units and median/mean CAC scores are given for the athletic cohort only. Some 
studies report median, others mean values, and these might therefore not be directly comparable. In 
the studies by Aengevaeren et al. and DeFina et al., data is given for subjects with the highest 
activity level.  
‡ Estimated value based on the published data.   
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The reasons for increased CAC in middle-aged recreational athletes are unclear. 
Shear stress forces and a hyperdynamic coronary circulation causing non-laminar 
flow during high-intensity exercise have been proposed to increase coronary artery 
calcification (39,43). Exercise-induced hypertension, systemic inflammation with 
repeated bouts of exercise and exercise-induced parathyroid hormone increases may 
also be involved in development of calcified CAD (39). Importantly, even with 
higher coronary artery calcium levels in highly active subjects than in the more 
sedentary population, active subjects did not have increased all-cause or CVD 
mortality as compared to sedentary subjects in a large 10-year follow-up study (42).  
Atrial arrhythmias  
Although moderate exercise is beneficial in preventing atrial fibrillation (AF), several 
studies have suggested an increased risk of AF in the most active individuals, 
particularly for men (44,55). The trigger is usually atrial ectopy (55). Atrial 
remodelling, with increased left atrial volume in athletes, has been associated with 
this increased prevalence of AF in athletes (56,57). Arterial hypertension, the most 
common cardiovascular risk factor among recreational athletes, has also been 
associated with increased risk of atrial arrhythmias (55). Other potential important 
modifiers of the arrhythmic risk in highly trained individuals might be the heightened 
vagal tone during rest, which leads to a shorter refractory period, and might enable 
macro re-entry tachycardia (55). An increased sympathetic tone during high-intensity 
exercise sessions might also modulate the risk of AF (55).  
Atrial fibrosis has emerged as a hallmark of atrial remodelling, and has been 
associated with atrial fibrillation recurrence post-ablation (58,59). The association 
between exercise, increased left atrial volume and atrial fibrosis has not yet been fully 
elucidated.  
Intermittent and underlying conditions  
Myocarditis may cause sudden death, and athletes with symptoms suggestive of 
myocarditis should be evaluated with CMR (60). The presence of LGE on CMR has 
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been found to be an independent predictor of mortality and major adverse cardiac 
events (61,62).   
Hypertrophic cardiomyopathy, arrhythmogenic (right ventricular) cardiomyopathy, 
dilated cardiomyopathy, non-compaction cardiomyopathy, congenital abnormalities, 
channelopathies, pre-excitation, valvular disease and myocardial bridging are 
examples of underlying conditions that often increase the risk of sport-related SCD. 
Some of these conditions have overlapping phenotypes with findings associated with 
physiological remodelling, and there are different risks associated with the different 
conditions. The European Society of Cardiology (ESC) sport cardiology section has 
outlined recommendations on sport participation for these different entities (63,64).       
5.6 Prevention of sport-related cardiac events 
 
Cardiovascular adverse events during strenuous exercise relates to a number of 
different etiologies. For younger subjects and competitive athletes, channelopathies, 
congenital abnormalities and cardiomyopathies are common underlying causes of 
sport-related cardiac arrest. For middle-aged and older subjects (≥35 years of age), 
coronary artery disease is the most prevalent cause (Figure 3) (5,65). This is important 





Figure 3: Age-dependent changes in incidents and etiology of sport-related sudden cardiac death 
(65). The Figure is used with the permission of the publisher.  
 
 
5.6.1 Young and competitive athletes 
For athletes between 12-35 years of age, it is estimated that about 0.5-2 out of 
100 000 athletes die suddenly each year (5,6). Men are more susceptible than women, 
and the risk increases with age (5).  
 
Current European recommendations for pre-participation evaluation of athletes 
include a medical history, physical examination and a 12-lead ECG (5). Inclusion of 
other imaging modalities do not add substantial diagnostic power (5). The evaluation 
has been found to have a sensitivity of 75 %, and up to 30 % of all evaluated subjects 
may need further testing (66). As such, mandatory pre-participation evaluation of 
young athletes is controversial (66).  
 
In Italy, introduction of a pre-participation evaluation for athletes was found to 
decrease sport-related SCD in from 3.6 to 0.4 per 100 000 person years over a 20 year 
period (67). Interestingly, these findings have never been reproduced in other cohorts 
(5). Currently the incidence of sport-related SCD is similar in France, USA and Italy, 
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suggesting that the pre-participation evaluation may not have been the cause of the 
reduced incident of SCD in Italy (66).    
 
The Union of European Football Association, among several other sport societies, has 
introduced a mandatory pre-participation evaluation of their athletes, including an 
echocardiogram. Malhotra et al., published data from 20 years of screening young 
English soccer players, including data from 11 168 athletes. They found that 0.38 % 
of the screened athletes had cardiac disorders that were associated with sudden 
cardiac death. During the follow-up period, 8 deaths due to cardiac disorders 
occurred, whereof 6 (75 %) had normal cardiac screening results (68). This is in line 
with a Norwegian study, which found that six professional soccer players (1 % of the 
total cohort), all of whom had a negative screening at baseline, suffered a serious 
cardiovascular incident over a 8 year follow-up period (69). These findings 
underscore the uncertainty of a pre-participation evaluation strategy.  
5.6.2 Senior athletes (> 35 years of age) 
For athletes > 35 years of age, the incidence of sport-related sudden cardiac death has 
been reported to be 1/15.000 – 1/50.000 (6).  
 
Pre-participation evaluation has been recommended for all active subjects ≥ 35 years 
of age who participate or plan to commence in strenuous physical activities (≥ 6 
METs) (70). In this group, CAD is the most common cause of sport-related SCD (5). 
The evaluation of these athletes is similar as for younger subjects, but identification 
of CV risk factors is given more attention.  
 
As for the younger athletes, there is considerable debate about the value of both a 
resting ECG and the maximal exercise test in subjects with no symptoms. Thus, the 
newer recommendations from 2017 states that for senior athletes, information should 
be given about the nature of cardiac prodromal symptoms, and that exercise stress 
testing is indicated if symptoms are present (5). Exercise stress test might also be 
considered in senior athletes with a high CV risk (5).  
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5.6.3 National practice  
A required systematic pre-participation evaluation of sports participants has not been 
implemented in Norway. For Olympic athletes, The Norwegian Olympic Sports 
Center (Olympiatoppen) offers a health evaluation, which includes an ECG. They 
offer a repeat evaluation when the athlete is 20, 25 and 30 years of age. Also, football 
players at the highest level are evaluated regularly, due to requirements from the 
Union of European Football Associations (71).  
5.6.4 Other preventive measures  
Sport-related sudden cardiac arrest (SCA) is still unavoidable. Bystander 
cardiopulmonary resuscitation and use of publicly available automated external 
defibrillators (AED) are strong predictors of survival of sport-related cardiac arrests 
(35). As such, it is important that coaches, staff at sport events and laypersons are 
skilled in cardiopulmonary resuscitation and the use of AEDs. Readily access to 
AEDs in exercise facilities and during sport events is beneficial in preventing sport-
related sudden cardiac deaths (35,72-75).  
5.6.5 Future perspectives  
There is consensus among both the American Heart Association and the European 
Society of Cardiology that “pre-participation evaluation for young competitive 
athletes is justifiable and compelling on ethical, legal and medical grounds” (6). Even 
so, there is considerable debate within the sport cardiology community about when to 
screen, which methods to use and how often a pre-participation evaluation should be 
carried out.   
 
A majority of subjects with sport-related SCA are asymptomatic prior to the event 
(7,8). This knowledge, combined with the low sensitivity and specificity of a resting 
ECG in identifying underlying CAD are major limitations of the current strategy of 
pre-participation evaluation, particularly in the senior athlete population where 
cardiomyopathies and channelopathies are less common causes of sport-related 
cardiac events. As such, there is a need to identify novel methods to assess 
asymptomatic recreational athletes. As this population engage in strenuous exercise 
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regularly, both for competitions and training, the use of these exercise sessions to 
evaluate physiological responses to exercise is an attractive avenue of research in this 
area. The use of cardiac biomarkers could potentially unmask a pathological response 
to exercise; however, the clinical consequences of exercise-induced cardiac 
biomarker increase need to be further elucidated.  
5.7 Cardiac biomarkers following strenuous exercise 
Several biomarkers change following strenuous exercise. The underlying 
mechanisms, the time-dependent dynamics and clinical significance of these 
biomarker changes are largely unknown. Changes in markers of cardiac injury 
(cardiac troponins), inflammation (C-reactive protein), cardiac strain (B-type 
natriuretic peptides), lipid changes, hormonal changes and electrolytes have all been 
described earlier. Most previous studies, however, have been limited by small cohorts 
or use of older biomarker assays. In addition, many studies only sample before and 
immediately after exercise, and all-male cohorts are prevalent.    
This current PhD project chose to focus on markers of exercise-induced cardiac 
injury (cTn) and inflammation (CRP). Cardiac troponins in this setting represent the 
acute cardiac stress-response to exercise, while inflammation is strongly associated 
with long-term cardiac events. Can these biomarkers assist in differentiating a 
physiological from a pathological response to exercise, and thereby aid in identifying 
subjects at risk of sport-related cardiac events?  
5.8 Cardiac troponins 
Assessment of cTn levels now constitutes the cornerstone in the diagnosis of 
myocardial infarction (acute myocardial injury), however, chronic myocardial injury 
with increased levels of cTn are also evident in patients with end-stage renal disease, 
in patients with arrhythmias, stroke, infections and even after non-cardiac surgery 
(76-81). In all these settings, increased cTn is associated with poor prognosis.  
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No long-term follow-up studies on cTn elevation following exercise had been 
published when this project was initiated, however, in 2014, Möhlenkamp et al. 
reported no adverse outcomes related to the exercise-induced cTn increase obtained 
immediately after a marathon in 74 marathon-runners (6±1 years of follow-up) (82). 
A very recent study by Aengevaeren et al. also assessed long-term outcomes of 
exercise-induced cTnI increase (83). In this study, a highly significant association 
was identified between all-cause mortality and major adverse cardiovascular events, 
and cTnI increase above the upper reference limit following a prolonged walking 
exercise in 725 participants (83). These findings suggest that exercise-induced cTnI 
increase may not be a completely benign, physiological response to exercise.  
5.8.1 Molecular basis  
Cardiac troponin (cTn) is an intracellular protein complex that consists of three 
subunits; Troponin I, Troponin T and Troponin C. Both cardiac specific isoforms of 
troponin I and T, and muscle troponin isoforms exist.  
Within the cardiomyocytes, the cTn protein complex is attached to tropomyosin, and 
is part of the thin filaments. Together with the thick filaments, these form the 
sarcomere, the contractible unit. When an action potential from the sinoatrial node 
reaches the cardiomyocytes, an influx of Ca2+ occurs, and calcium binds to the 
troponin C subunit. This in turn leads to a conformational change in the cTn protein 
complex, and myosin binding sites on the actin filaments on the thin filaments are 
exposed, ultimately leading to muscle contraction (84). In addition to cTn bound to 
tropomyosin, cTn molecules are also present in a loosely bound form in the cytosol 
(85).  
 
Troponin I is the actomyosin ATPase inhibiting subunit of the troponin complex. The 
gene that codes for cTnI is located on chromosome 19 (q13.4) (86). There are two 
other TnI isoforms: slow skeletal muscle TnI (ssTnI, 1q31.3) and fast skeletal muscle 
TnI (fsTnI, 11p15.5), both of whom are smaller molecules encoded for by genes on 
chromosome 1 and 11, respectively. Cardiac troponin I consists of 210 amino acids, 
and has a molecular weight of 24 kDa (86). The cardiac isoform of TnI has 
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similarities to ssTnI and fsTnI, but differs primarily by having a unique N-terminal 
extension (residues 1-30 for cTnI) (86). Post-translational modifications may be a 
significant factor in regulating the function of cTnI, particularly the process of 
phosphorylation, but this is not fully understood (86).  
 
The troponin T subunit binds to tropomyosin, and has likely evolved from a TnI-like 
ancestor protein, prior to the emergence of vertebrates (87). Similar as for TnI, there 
are three genes that encode for troponin T; the cardiac isoform (1q32), the slow 
skeletal muscle isoform (19q13.4) and the fast skeletal isoform (11p15.5). As for TnI, 
the main structural difference between these isoforms is in the N-terminal region. 
Cardiac TnT has a molecular weight of about 37 kDa (84,87). Alternative splicing 
has been described for cTnT, and has been associated with cardiomyopathies. Post-
translational regulation by phosphorylation has been described in vitro, however, this 
requires further investigation (87).  
 
5.8.2 Analytical considerations  
Different cTnI assays uses monoclonal antibodies specific to different epitopes of 
cTnI, and as such, standardization of cTnI measurements has proved difficult (88). 
Circulating cTnI is usually bound to cTnC (> 95 %), and detection of cTnI is 
influenced by proteolytic degradation, phosphorylation, heparin, and type of assay 
(88). 
The high-sensitivity cTnT assay by Roche Diagnostics (fifth generation) uses 
monoclonal antibodies that binds to the central region of cTnT (88).  
Both the high-sensitivity cTnI (Abbott) and the cTnT (Roche) assays used in this 
thesis have a low degree of imprecision (coefficient of variation < 10 % at the 99th 
percentile) (88). For Paper 1 in this thesis, the local overall 99th percentile for the 
cTnI assay was used, as determined by internal validation data at the Department of 
Biochemistry, Stavanger University Hospital (30 ng/L). For Papers 2-3 the overall 
and the sex-specific 99th percentiles was obtained by data from a more comparable 
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population of middle-aged blood donors (cTnI: overall 26 ng/L, males 28 ng/L, 
females 22 ng/L cTnT: overall 14 ng/L, males 16 ng/L, females 10 ng/L) (89).   
After cTn enters the blood stream, degradation begins (90,91). This process is not 
fully understood, but might include phosphorylation, ubiquitination, complex-
formation and binding to specific anti-cTn immunoglobulins (92). For patients with 
myocardial infarction, cTnT has been found both in an intact form (37 kDa), and in a 
primary fragment (29 kDa) and in several smaller secondary fragments (15-20 kDa) 
(91). The primary fragment is cleaved by the N-terminal end of the cTnT, while the 
secondary fragments are further cleaved by the C-terminal end (91,93). For subjects 
with end stage renal disease, and in a small study of marathon runners, only 
secondary cTn fragments were identified (94,95). Targeting the C-terminal end of 
cTnT in future assays might be useful to differentiate between cTnT forms in patients 
with chronic cTn elevations, physiological cTn elevations (i.e following exercise) and 
cTn due to irreversible cardiomyocytes damage. The major limitation in this research, 
however, is the limit of detection for the used methods; the mass spectrometry assay 
has a limit of detection of 1000-8000 ng/L, gel filtration chromatography has a limit 
of detection of about 70 ng/L (92,95).  
The secondary cTn degradation fragments (<20 kDa) might possibly pass over the 
glomerular membrane for clearance (96). After an acute myocardial infarction, 
however, extra-renal clearance dominates in studies on rats (97). Extra-renal 
clearance might be associated with scavenger receptor clearance; however, this topic 
has not been fully elucidated.  
 
5.8.3 Increase in cardiac troponin due to necrosis of cardiac 
myocytes 
When the coronary blood flow is obstructed, ischemic cell death occurs. The 
subendocardial myocardium, which receives the least blood flow, is most susceptible 
to ischemic injury (98). With restoration of blood flow, myocardium might be 
salvaged. Timing, however, is important, and animal models have shown that after 6 
hours of ischaemia, essentially no salvage occurs with reperfusion (99).   
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Early histological studies described myofibrillar contraction bands in necrotic 
cardiomyocytes; a process mediated by an influx of Ca2+ into the cytoplasm, leading 
the sarcomeres to contract tonically and consume the remaining ATP (99). This limits 
the cardiomyocytes’ ability to pump out excess Ca2+, and the cross-bridges between 
actin and myosin remain in an attached state. This in turn, leads to formation of 
sarcolemmal blebs, and eventually to disruption of the cellular membrane (99). Also, 
swelling of the mitochondria and destruction of the microvasculature occur (99).  
 
After a transmural myocardial infarction, cTnI and cTnT are released within minutes 
after the cellular damage, and remain elevated for days after the infarction. This is in 
contrast to other intracellular molecules, such as creatine kinase and lactate 
dehydrogenase, where normalization of plasma levels is seen more rapidly. This 
prolonged elevation of cTn is most likely due to the binding between cTn and thin 
filaments of the sarcomere, which slows the washout of these molecules (96).  
 
In the setting of an acute myocardial infarction, slight differences in the cTnI and 
cTnT kinetic pattern has been identified, with a prolonged or “biphasic” release of 
cTnT (100).  
 
5.8.4 Increase in cardiac troponin due to apoptosis  
Apoptosis of cardiomyocytes is cell death due to cell body fragmentation and 
engulfment by resident cells (101). Apoptosis can be triggered both by an extrinsic 
and an intrinsic pathway, and the mechanisms are complex (102). Since no 
intracellular content is expected to be released with apoptosis, it has been suggested 
that apoptosis cannot be a source of cTn elevation (96,103). Destruction of apoptotic 
bodies with release of cTn could possibly be a source for cTn release, however, this 
has never been proven (96). More research is needed on cTn release in relation to 
apoptosis (96).  
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5.8.5 Increase in cardiac troponin due to cell wounds 
When cardiomyocytes are stressed by contraction, ischaemia, stretched by external 
forces or by beta-adrenergic stimulation, extracellular macromolecules have been 
detected in the cytoplasm of cardiomyocytes (96,104,105). These macromolecules 
enter the cell through gaps in the plasma membrane, so called cell wounds (96).  
Cells have mechanisms to protect against cell destruction due to cell wounds, and 
small holes in the plasma membrane are usually repaired within seconds (106). 
Mutations in genes involved in cell wound repair have been identified in three 
muscular dystrophies: Limb-girdle muscular dystrophy type 2B, Miyoshi myopathy 
and distal anterior compartment myopathy (107). For mice with mutation in these 
genes, cardiomyopathy and stable cTn elevations have been found (108). Cell 
wounds have therefore been proposed as a mechanism of cTn release from the 
cytosolic pool from viable cardiomyocytes, however, there is still limited 
understanding of this phenomenon (96).  
 
5.8.6 Increase in cardiac troponin due to cross-reactivity with 
skeletal muscle  
Both the cTnI assay by Abbott, and the cTnT assay by Roche use antibodies that bind 
to the cardiac isoforms of cTn. For the cTnT assay by Roche, cross-reactivity with 
skeletal muscle has been observed in patients with myopathies (109,110). No cross-
reactivity has been described for the cTnI assay (109,110). This phenomenon of 
cross-reactivity was not found in a cohort of subjects with rhabdomyolysis (111). The 
effect of exercise-induced muscle injury in relation to cTnT cross-reactivity is 
uncertain.  
 
5.8.7 Cardiac troponin in the general population and as a risk 
marker 
Healthy blood donors have a median cTnI (Abbott) of 2.5 (2.4-2.5) ng/L with a 99th 
percentile of 28.9 (23.1-41.1) (89). The corresponding median cTnT (Rohce) 
concentrations in the same cohort was 2.7 (2.6-2.8) ng/L and a 99th percentile of 15.9 
(14.6-18.3) ng/L (89). Baseline cTn increase with age and male sex (89,112). Higher 
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cTn levels have also been associated with body mass index (BMI), blood pressure, 
NT-proBNP, CRP and history of diabetes mellitus (113). An inverse relationship 
between smoking and cTn has also been described (113,114). Having higher baseline 
cTn is associated with an increased risk of future CVD (112,113,115).  
 
5.8.8 Increase in cardiac troponin due to exercise 
Cardiac troponin levels have been described to increase with exercise in several 
studies, the largest of whom is the study by Fortescue et al. (116,117). The exact 
mechanisms of exercise-induced cTn increase are largely unknown, but likely relate 
to cell wounds, as described in chapter 5.7.6 (118). It has been described that 
macromolecular exchange over the plasma membrane occurs in Petri dishes, and that 
this macromolecular exchange increases with contraction or stretching of 
cardiomyocytes (118). As regeneration of cardiomyocytes is limited, cTn increase 
due to necrosis is highly unlikely to be the main underlying cause of exercise-induced 
cTn increase (118). 
 
At the time of the NEEDED study design, there was uncertainty about the magnitude 
and expected kinetics of cTn following prolonged cycling. With the use of older cTn 
assays, many study participants did not have detectable cTn levels following cycling 
events, despite several sampling time-points (119-121). Based on the study by 
Sharhag et al. a continued increase to three hours post-exercise was noted for cTnI, 
and possibly for cTnT following a cycling event in 45 subjects (122). These findings 
of a continued increase were supported by findings of studies on other exercise 
modalities (123,124).  
 
The predictors of exercise-induced cTn increase had been reviewed by Shave et al in 
2007, and they concluded that race duration and body mass were associated with 
detectable cTn following exercise (125). This meta-analysis included 26 studies, but 
was limited by assessing cTn immediately following exercise and by the use of older 
cTn assays. Eleven of these studies included only male subjects. As such, the 
predictors of exercise-induced cTn increase, particularly when studied as a 
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continuous variable, were largely unknown. No studies had assessed the relationship 
between coronary artery disease and exercise-induced cTn. Also, no long-term 
follow-up studies on exercise-induced cTn increase and clinical events had been 
published prior to the design of the NEEDED study.  
 
In 2014, Möhlenkamp et al. published the first long-term follow-up study in this 
research area, and found no association between clinical endpoints and exercise-
induced cTnI obtained immediately after a marathon in 74 subjects (82). There was 
also no association between coronary artery calcium (CAC) and exercise-induced 
cTnI (82). Only 6 marathon finishers, however, suffered an event (82). With 
underpowered studies, there is a risk of type 2 errors, and as such, this finding needed 
to be confirmed in larger cohorts.  
 
A recent study published by Aengevaeren et al. followed 725 subjects after a 30-55 
km walking exercise for a median of 43 months (83). In this study, median age was 
61.4 years, and CV risk factors and CVD were prevalent (36 % and 14 % 
respectively) (83). cTnI was obtained immediately after the exercise, and 9 % of 
subjects were found to have a cTnI above the upper reference limit (0.04 µg/L, older 
cTnI assay used) (83). The combined endpoint of all-cause mortality, myocardial 
infarction, stroke, heart failure, revascularization or sudden cardiac arrest occurred in 
62 subjects (9% of the cohort). Subjects with cTnI above 0.04 µg/L following the 
walking exercise had significantly higher risk of suffering a primary endpoint during 
follow-up (hazard ratio (HR): 5.21 (95 % confidence interval (CI): 2.96-9.17), 
p<0.001), also when adjusting for age, sex and CV risk factors, CVD and baseline 
troponin values (HR 2.48 (95 % CI: 1.29-4.78), p=0.01) (83). This study challenges 
the concept that exercise-induced cTn increase is a completely benign, physiological 
response to exercise. The finding, however, is not readily transferable to younger, 
healthier subjects engaged in strenuous activity, where cTn increases above the upper 
reference limit is highly prevalent. The role of later cTn sampling was also not 
elucidated.  
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5.9 C-reactive protein 
C-reactive protein (CRP) is an inflammatory marker that has been highly conserved 
throughout evolution. It was discovered by Tillett and Francis in 1930 and named due 
to its reactivity with phosphocholine residues of C-polysaccharide on Streptococcus 
Pneumoniae (126). CRP together with serum amyloid P-component (SAP), are part 
of the highly conserved Pentraxin protein family. No conditions with human CRP 
deficiency has been identified, suggesting that this protein is highly important for our 
survival (127).  
5.9.1 Molecular basis 
The gene that codes for CRP in humans has been located on chromosome 1, and 
synthesis of CRP occurs primarily in the liver (127). The CRP protein complex is 
made up of a single polypeptide chain of 206 amino acids, and consists of five 
subunits that are arranged in a flat disc (127). CRP gene transcription is regulated by 
cytokines, especially Interleukin-1β, Tumor necrosis factor-α and Interleukin-6. The 
molecular weight of CRP is approximately 120 kDa (127).  
CRP can be found in three isoforms: a multimeric form (≥ 10 subunits), the native 
pentameric form and as a monomeric CRP (1 subunit) (127). The physiological roles 
of the multimeric and monomeric CRP forms have yet to be established with 
certainty (127).  
5.9.2 Analytical considerations 
CRP is a readily available biomarker, and has a half-life of approximately 19 hours 
(127). It can be measured both in fresh, stored or in frozen plasma, and is stable in 
plasma or whole blood for at least 3 days (128). With the use of contemporary high-
sensitivity CRP assays, concentrations as low as 0.15 mg/L may be detected. With the 
current widespread use, it has become an inexpensive test, used to test patients with 
suspected infections, inflammatory disorders and to determine CV risk.   
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Degradation of CRP occurs in the liver, and follows a stable exponential trajectory 
even in subjects with active infections (129,130). As such, the rate of CRP synthesis 
is the primary determinant of CRP increases.   
5.9.3 Increase in CRP due to acute inflammation and injury   
CRP exists only in trace serum concentrations in humans, and act as an acute phase 
reactant. It has the ability to increase 1000-folds in response to infection, tissue injury 
and inflammation (131).  
CRP binds phosphocholine (and a variety of other ligands) at one side of the disc-like 
structure (the B face or the recognition face), and activate the classical complement 
system (C1q) on the opposite side (127,132). Binding of ligands is dependent upon 
calcium. By activating the complement cascade, phagocytosis occurs. As such, CRP 
is highly important in defending against bacteria.  
CRP also binds to phosphocholine on injured cells, and activates the complement 
cascade (133). This is beneficial for most tissues, and leads to removal of dead cells. 
For tissues with a low rate of regeneration, i.e. heart muscle, this binding might be 
harmful (133). In the setting of a myocardial infarction, there are injured cells with a 
potential for survival in the area surrounding the necrotic zone. In animal models, 
CRP has been found to increase the infarct size and aggravate left ventricular 
dysfunction due to this binding to injured myocytes (133). An association between 
CRP increase post-myocardial infarction and infarct size has also been demonstrated 
in humans (134).  
5.9.4 Increase in CRP due to chronic inflammation  
Atherosclerosis is a complex disease, and inflammation is a vital part of the disease 
process (132). At the early phases of atherosclerotic plaque formation, leukocytes 
(monocytes) are recruited by proinflammatory cytokines (135). As the plaques 
develops, monocytes are differentiated into macrophages, and these macrophages 
engulf lipoproteins, and becomes foam cells (132,135). These cells secrete 
chemokines and cytokines that contribute to more leukocyte accumulation, smooth 
muscle cell proliferation and remodelling (132). Inflammation is also important in 
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degradation of the fibrous cap of the plaque, leading to plaque vulnerability and 
possible rupture (132). A ruptured plaque with formation of a thrombi is usually the 
origin of an acute cardiovascular event.  
 
From the 1990s, several observational studies found that slight increases in CRP were 
independently associated with increased risk of CV morbidity and mortality (136-
138). Statin-trials in this era also found that lowering LDL was associated with lower 
CRP levels, further inferring to the complex association between lipids and 
inflammation in atherosclerotic disease (139-141). Lowering lipids by the use of 
proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, however, has not 
been associated with decrease in CRP levels (142,143).  
 
In order to establish a causal link between higher basal inflammation and future 
CVD, a study that targeted proinflammatory cytokines upstream to CRP were 
indicated. The CANTOS trial chose to target IL-1β, a cytokine involved in expression 
of cell surface proteins that increase inflammatory cell adhesion, and which 
stimulates vascular smooth muscle cell proliferation and upregulates IL-6 
(135,144,145). In this randomized, double-blinded placebo-controlled trial, subjects 
were included if they had a CRP level ≥ 2 mg/L, and were followed for a median of 
3.7 years. Subjects who received Canakinumab, the IL-1β antagonist, experienced a 
decrease in CRP level, but had no difference on LDL levels. A 15 % relative 
reduction in major adverse cardiac events was observed for subjects taking 
Canakinumab at 150/300 mg doses, as compared to the placebo group (p=0.007) 
(144). Further analyses showed that the effect was most pronounced in subjects who 
achieved a CRP concentration < 2 mg/L after the first dose, a finding that persisted 
throughout the study period (25 % risk reduction for major adverse cardiac events in 
this group) (146). It is important to note, however, that CRP reflects upstream 
processes, and there is no evidence that CRP is the cause of disease (133).  
5.9.5 CRP in the general population and as a risk marker 
Healthy subjects have a median CRP concentration of 0.8 mg/L, with the 90th 
percentile at 3 mg/L and the 99th percentile at 10 mg/L (131,147). CRP levels tend to 
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increase with age, obesity and current smoking (131). Cohort studies have found that 
baseline CRP levels < 1 mg/L implies a low risk of future CV risk. Levels between 1-
3 mg/L are considered intermediate risk, while levels > 3 mg/L are considered high 
risk of future CV events (131).  
5.9.6 Increase in CRP due to exercise 
Exercise-focused interventional trials have been shown to lower CRP-levels, 
particularly when accompanied by weight loss (148,149). Physical activity level has 
also been associated with lower CRP-levels in community-based studies (150,151). A 
bout of acute exercise, however, generates an increase in CRP levels. This is an acute 
phase reaction, mediated by an exercise-induced increase in a number of cytokines, 
and in particular IL-6 (152). IL-6 is has been described to increase 100-fold following 
strenuous exercise, and is the cytokine with the earliest peak concentration (153,154). 
As described in chapter 5.8.1, IL-6 stimulates CRP synthesis in the liver.   
 
Weight et al. studied 90 marathon runners, and found that CRP increased from 1.1-
22.7 mg/L, p<0.01 (155). Several smaller studies have confirmed this finding, and 
exercise duration, modality, and increase in creatine kinase have been associated with 
the magnitude of the CRP increase (152). Some studies, however, have not been able 
to demonstrate a significant CRP-response to exercise (156,157). Scharhag et al. found 
that 4 hours of cycling only yielded an increase in CRP from 0.5-1.8 mg/L from 
baseline to 24 hours following exercise in their cohort of 12 young athletes (156). 
Prior to the NEEDED study, the effect of cycling on exercise-induced CRP was 
uncertain, and many of the prior studies had only included highly trained male 
subjects (152). A meta-analysis from 2015 of the acute effects of exercise in 
untrained subjects was only able to identify two studies on CRP (n=12 and n=14), 
and the exercise-induced CRP increase was not significant in these cohorts (158). As 
such, both the kinetics, magnitude and predictors of the exercise-induced CRP 
increase was largely unknown at the time of the design of the NEEDED study. Also, 




Repeated bouts of exercise with its accompanying exercise-induced inflammatory 
response has been suggested to be related to increased CAC and CAD among highly 
active recreational athletes (39,159). Inflammation, and particularly IL-6, has also 
been associated with SCD in the general population (160-162). The link between 
exercise-induced myocardial injury, CAD and inflammation is therefore a compelling 
avenue of research within the field of sport cardiology.     
5.10 Imaging modalities for identification of coronary artery 
disease in recreational athletes 
Imaging modalities for assessment of CAD includes functional tests of ischemia and 
anatomical visualisation of the coronary arteries. The most commonly used functional 
tests are exercise ECG, stress echocardiography, myocardial perfusion scintigraphy, 
stress CMR and hybrid techniques. The anatomical assessments include coronary 
computed tomography angiography (CCTA), CMR coronary angiography and 
invasive coronary angiography.  
 
Braber et al. reviewed the literature surrounding imaging of CAD in recreational 
athletes, and found that CCTA with calcium scoring was the modality with the 
highest diagnostic value (163). Calcium scoring from CT imaging is possible without 
the use of contrast, and with a low dose of radiation (<1 mS) (164). Pixels > 130 
Hounsfield units are defined as coronary calcium, and quantified as Agatston units 
(165). The association between coronary calcium and degree of luminal obstruction, 
however, is poor. Subjects with a zero calcium score may also have severe plaques of 
a non-calcified nature (165). CCTA is a non-invasive method of determining the 
presence and severity of CAD. The method has a sensitivity of 95-99 % and a 
specificity of 64-83 % in diagnosing the presence of coronary artery disease (165). 
Radiation exposure is between 1-10 mS, and requires intravenous contrast (6). The 
quality of CCTA is influenced by heart rate, body weight and severe calcifications 
and prior stents. In order to achieve a heart rate < 65, short acting beta-blocking 
agents are used when appropriate. A meta-analysis found that cardiac death or MI 
occurred in 0.04 % of subjects with no CAD on CCTA, as compared with 1.29 % in 
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subjects with non-obstructive CAD and 6.53 % of subjects with obstructive lesions 
(166).  
 
Functional imaging modalities for assessment of CAD, such as exercise-stress 
echocardiography (sensitivity of 80-85 %, specificity 80-88 %), stress CMR 
(sensitivity 79-88 %, specificity 81-91 %) and myocardial perfusion scintigraphy 
(sensitivity 90-91 %, 75-84 %) are robust tools to detect significant CAD, however, 
they are costly and have low availability (6,163,165). Exercise ECG testing is widely 
available, however, this test has a limited sensitivity (45-50 %) for detecting CAD, 
particularly in a cohort of subjects with low (<15 %) pretest probability of CAD 
(165).  
 
Echocardiography alone has limited value in identification of CAD, but is an 
important imaging modality for assessing structural cardiac abnormalities (163). 
CMR allows for excellent assessment of cardiac function and of LGE without 
exposure to radiation (163). CMR angiography for anatomical assessment of the 
coronary arteries is a novel tool with the advantage of no radiation exposure. This 
method however, still offers limited visualization of the coronary arteries, and is 
currently most used in research (163,165).  
 
Invasive coronary angiography is not a first-line test in low-risk subjects due to the 
higher risk of complications as compared with non-invasive imaging modalities. It 
uses intravenous contrast and exposes the patient to radiation (2-7 mS) (6). A 
valuable attribute of the invasive procedure is the possibility of estimating the 
fractional flow reserve in order to determine if a stenosis is clinically significant, and 
allows for the use of advanced intra-coronary imaging to assess plaque features.  
5.11 Summary   
Regular exercise is highly beneficial. Strenuous exercise, however, does carry a small 
risk of sudden cardiac events. More than 90 % of sport-related SCA occurs among 
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recreational athletes, and for senior athletes (> 35 years of age) CAD is the most 
common underlying cause (6,35). The majority of victims of sport-related SCA are 
asymptomatic prior to the event (7,8).    
Current guidelines recommend pre-participation evaluation of all athletes who 
participate in strenuous exercise (5). The ability of a clinical history and a resting 
ECG to detect underlying CAD, however, is limited (66). As such, there is a need to 
identify novel methods to assess asymptomatic recreational athletes. As this 
population engages in strenuous exercise regularly, the use of these exercise sessions 
to evaluate physiological responses is an attractive avenue of research in this area.  
Cardiac troponins are markers of myocardial injury, and increased levels have been 
associated with increased risk of cardiovascular mortality and morbidity, recently 
also following exercise (83). This biomarker is therefore of major interest in detecting 
potentially pathological responses to exercise. Higher basal inflammation has also 
been identified as a risk factor for CVD, and has been associated with SCA 
(132,160). Furthermore, it has been suggested that there might be an association 
between exercise-induced inflammation and increased CAD in athletes (39,159).  
In this project, the physiological and potential pathological pattern of exercise-







6.1 General aims of the thesis 
In this work, we aimed to identify the physiological pattern and predictors of 
exercise-induced cardiac troponin and C-reactive protein within 24 hours following 
strenuous exercise. Secondly, we aimed to identify a potential pathological response 
to exercise in a subset of subjects, and associate this with underlying coronary artery 
disease. 
6.2 Specific aims 
6.2.1 Paper 1 
First, identify the magnitude and time-dependent changes of the exercise-induced 
cTnI response following the North Sea race. Secondly, to assess subjects with highly 
exercise-induced cTnI values for underlying CAD. This study was used to determine 
the design of the NEEDED 2014 study (Papers 2-3).   
6.2.2 Paper 2 
To identify the most important predictors associated with the cTn response following 
strenuous exercise in a large cohort of healthy recreational athletes.  
6.2.3 Paper 3 
To compare the exercise-induced cTn profiles in presumably healthy recreational 
cyclists with and without coronary artery obstruction identified by CCTA in order to 
separate a physiological from a pathological cTn response.  
6.2.4 Paper 4 
First, to identify the magnitude and time-dependent changes of the exercise-induced 
C-reactive protein response following the North Sea Race. Secondly, to identify the 
most important predictors associated with the CRP response following strenuous 
exercise. Third, to identify a potential relationship between exercise-induced CRP 
and cTn.  
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7. Materials and Methods 
Paper 1 and 4 in this thesis used material from the NEEDED 2013 pilot study, while 
paper 2-3 used material from the main study, NEEDED 2014. Both studies centers on 
the completion of the North Sea Race, a 91 km cycling competition. The pilot study 
included 97 subjects, while the main study included 1002 subjects. Similar protocols 
for data collection were used both years, but up-scaled 1:10 for the main study.   
7.1 Study organization, approval and registration   
Professor Stein Ørn, MD, PhD initiated the NEEDED study. The board includes Dr. 
Tor Harald Melberg, MD, PhD of the Cardiology Department, Dr. Øyvind Skadberg, 
MD, Department of Biochemistry, Dr. Rolf Bergseth, MD, Medical officer for the 
North Sea Race, Torbjørn Aarsland, Research Department., and Jone Selvaag, 
Department of Biochemistry. The protocol was written by Ørn and Melberg, and 
approved by the board. The study was approved by the regional ethics committee 
(2013/550/REK vest), and registered in clinicaltrials.gov (NCT02166216 
https://clinicaltrials.gov/ct2/show/NCT02166216).  
7.2 Study populations, inclusion and exclusion criteria   
The choice of study population was based upon the following assumptions; 1) Most 
sport-related cardiac events occurs among recreational athletes, 2) Cycling events 
attracts a more diverse cohort of recreational athletes, as weight is carried by the bike, 
and down-hill segments allow for periods of rest. This would allow subjects with a 
lower degree of physical fitness to participate, as compared to long-distance running-
events. This was important, as we wanted a large cohort of athletes, ranging from 
those with very limited training experience, to those who had elite competition 
experience.  
The North Sea Race was an ideal endurance exercise event; they attracted a large 
cohort each year, had a professional organization, and the organizing committee was 
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genuinely interested in participating in this research, as they had first-hand experience 
with sport-related cardiac events.  
Study participants were recruited via the Internet, via the official web page of the race 
organizers (www.nordsjorittet.no). All participants in the North Sea Race in 2013 and 
2014 were invited. In 2013, the Internet based invitation to participate was closed 
after 169 cyclists had signed up. A total of 111 cyclists signed the informed consent, 
and 97 cyclists completed the race and the study assessments. In 2014, registration 
was closed after 1250 subjects had signed up. In total 1002 participants were included 
in the main study.  
Subjects had to be ≥ 16 years of age, sign the informed consent and reside in Norway 
in order to be included in the studies. Subjects were excluded if they reported any CV 
symptoms or treatment for CVD (including CAD, stroke, diabetes mellitus or 
hypertension requiring medical treatment). Participants were also excluded if the 
baseline 12-lead ECG had signs of underlying CV disease: Q-waves (>3mm in depth 
or > 40 ms in duration in two or more leads except III, aVR and V1), T-inversions 
(>1 mm in depth in two or more leads in V2-6, II and aVF, or I and aVL), left bundle 
branch block or atrial or ventricular tachyarrhythmia. Subjects were excluded from 
the analyses if they did not complete the study assessments.  
7.3 Data collection 
Data collection in the 2014 study was based upon experiences from the 2013 study. 
Study subjects were first assessed 24 hours prior to the race (baseline). In 2013 
subjects were then assessed both immediately and 3 hours after the race, while in 
2014 assessments were obtained only 3 hours after the race. Both years, a final 
assessment was obtained 24 hours after the race.  
Figure 5 outlines the logistical system that was developed for a comprehensive 30 
minutes assessment of each of the study subjects in 2014. In 2013, a simplified 
version was used, with three lines.  
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Figure 5: Flow diagram of data acquisition before and after the North Sea Race in 2014. Logistics 
related to handling of study subjects at the finish line and transportation of samples to Stavanger 
University Hospital for analysis is not included in the diagram. A total of 157 study personnel were 
required to complete the study. The Figure was developed by G. Jonasson, and has been edited by 
Dr. Kleiven.   
 
Assessments included registration, resting 12-lead ECG, resting blood pressure, body 
weight, blood sample acquisition and ECG interpretation and clinical assessment by a 
cardiologist. Waist circumference was obtained in 2014. Questionnaires were 
obtained at baseline, shortly after the race, 24 hours after the race and 1 week after 
the race, outlining training habits (including the standardized International Physical 
Activity Questionnaire (IPAQ-SF)), prior medical history, height, nutrition and post-
race status. A fifth questionnaire was completed by female participants 2014, 
outlining hormone therapy, menarche, menopause, and childbirths. Race duration was 
registered electronically by the official organizer of the race. For subjects who used 
personal heart rate monitors, data on mean and maximal heart rate during the race 
was collected both years. In 2014, files from advanced heart rate monitors were 
collected electronically for further analysis when available (n=181).  
The decision to not include an assessment immediately after the race in 2014 was 
based on logistical concerns: > 2000 assessment of approximately 30 minutes per 
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person over a 12-hour period was not considered feasible. As cardiac troponin levels 
were highest at 3 hours after the race, this was the chosen sampling time.  
7.4 The North Sea Race 
The North Sea Race is a cycling competition from Egersund to Sandnes (91km), and 
about 40 % of the track is on trails and mountain terrain. This race was first organized 
in 1998, and has grown in popularity, with a peak in participation in 2011 (Figure 2). 
The motto of this race is “For folk flest”, which loosely translates to “for ordinary 
people” and implies that limited prior exercise is needed in order to participate in this 
race. The organizers of the race also encourage local businesses to enroll teams and 
use the race as a team-building exercise. Race duration varies with weather 
conditions; however, a mean race duration between 4.0-4.5 hours is common.   
During the race, safety is highly important. Six ambulances are placed at strategic 
points along the trail. Additionally, six teams with all-terrain vehicles (ATVs) are 
stationed in areas with difficult access. A total of 80 personnel covers the medical 
stations along the trail and at the finish line. The approximately 300 personnel posted 
along the trail are also trained in administering chest compressions and first aid, if 
needed.    
Age- and sex distribution in the North Sea Race of 2014 is outlined in Figure 4. A 
total of 11 413 subjects signed up for the race in 2014, however, only 8678 (76 %) 
finished the race. The mean race duration was 4 hours and 13 minutes (men: 
4:04±0:57, women: 4:51±1:03 hours).  
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Figure 4: Age and sex distribution among subjects who finished the North Sea Race in 2014 
(n=8678, blue=men, red=women).   
 
7.5 Blood samples 
Venous blood samples were acquired from an antecubital vein at all assessments (4 
times in 2013, 3 times in 2014). All samples were handles by professional medical 
personnel. Serum samples were centrifuged within 60 minutes at 2000 G for 10 
minutes, and analyzed for creatinine, B-type natriuretic peptide (BNP), high-sensitive 
C-reactive protein (hs-CRP), low density lipoprotein, high density lipoprotein, 
creatine kinase (CK) and CK-myocardial band (CK-MB) on Architect c16000TM 
(Abott Diagnostics, Illinois, USA). For hematology, 3 ml K2 
Ethylenediaminetetraacetic acid (EDTA) tubes were used, and the samples were 
analyzed on XE-5000 (Stsmex, Kobe, Japan). The tubes were stored at room 
temperature until analysis. Tubes without any additives were placed in room 
temperature and centrifuged after coagulation at 20000 G for 10 minutes. Following 
centrifugation, all blood samples were stored at +4 degrees C and transported to the 
Department of Biochemistry at Stavanger University Hospital for analysis.  
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Cardiac troponin I was analyzed using the high-sensitivity cTnI STAT assay by 
Abbott Diagnostics, analyzed on an Architect i2000SR (Abbott Diagnostics, Illinois, 
USA), with a lower limit of detection of 1.6 ng/L. Frozen samples were transported 
on dry ice to Haukeland University Hospital, Bergen, and cTnT was analyzed using a 
high-sensitivity cTnT assay on Cobas e601 (Roche Diagnostics, Switzerland) in 
serum that had not been previously thawed. The cTnT assay had a limit of blank of 3 
ng/L.   
CRP was measured in serum. The local analytical variation (CV) is <3 % at 24 mg/L.  
In 2013, glycated hemoglobin (HbA1c) was measured at baseline on Variant Turbo II 
(BioRad Laboratories, California, USA). Copeptin (analyzed on Kryptor Compact 
Plus, B.R.A.H.M.S. GmbH, Thero Fisher Scientific, Hennigsdorf, Germany) was also 
obtained in 2013, but not in 2014.  
7.6 Coronary computed tomography angiography  
Coronary calcification and CCTA was obtained using a Siemens Somatom Definition 
Flash Dual Source. Slice acquisition parameter was 0.6 x 128 mm. Those with heart 
rate more than 60 beats per minute were given atenolol or metoprolol tartrate prior to 
examination. All were given 0.8 mg nitroglycerine sublingual before the scan. A 
scout scan was performed from under the tracheal bifurcation to the diaphragm, 
followed by CT calcium score scans with gantry rotation 280 ms, 12 kV, 80 mAs. A 
two-phase injection of Omnipaque 350 mg/ml at a rate of 6 ml/sec followed by 0.9 % 
saline with high pitch or prospectively ECG triggered protocols were administered. 
CCTA was reconstructed with slice thickness of 0.6 mm medium smooth tissue 
convolution and iterative reconstruction.  
Obstructive CAD was defined as ≥ 50% luminal stenosis in the left coronary artery, 
the right coronary artery, the circumflex artery, or a diagonal or marginal branch. The 
CCTA examinations were independently assessed by two experienced radiologists, 
blinded to the cTn findings. Non-obstructive CAD was defined as a luminal 
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narrowing of 1-50%. Subjects with obstructive CAD on CCTA were referred for 
conventional coronary angiography and treated with percutaneous coronary 
intervention or coronary artery bypass grafting, as determined by the cardiologist 
performing the angiography.  
In the pilot study (NEEDED 2013), study subjects were referred for a coronary 
computed tomography angiography (CCTA) or to a conventional coronary 
angiography, if they had cTnI > 500 ng/L at any time following the race 
(predetermined cut-off based upon our own non-published data from elite cyclists). 
We considered this cut-off to be the upper boundary of a physiological cTn response. 
As both subjects with cTnI > 500 ng/L had coronary artery disease, a post-hoc 
decision was made to scan subjects with descending cTn values until no more CAD 
was identified in 5 consecutive scans. Based on the findings from the pilot-study, a 
cut-off of 201 ng/L was determined as a guide to the planning of CCTA assessments 
in the main study.  
In 2014, it was considered that including the 80 subjects with the highest cTnI values 
at any time following the race would roughly comply with the proposed cut-off of 
201 ng/L from the pilot-study (8 subjects had cTnI > 201 ng/L in the pilot study). 40 
subjects, matched for age and sex, with moderate cTnI increase after the race were 
assessed as a reference group. The reference group was an amendment to the 
protocol, and CCTA was obtained 3-12 months later in these subjects (see Chapter 
10.12 for further details).  
7.7 Statistical analysis 
Descriptive statics was used in all the Papers, using mean±SD to describe normally 
distributed continuous variables, and median (25th-75th percentile) for variables with 
markedly skewed distributions. The Shapiro-Wilk test was used to test for normality. 
Number (%) was used to describe frequencies. Chi-Square test, Fisher’s Exact test, 
Student t-test or Mann-Whitney U test was used for comparison of groups, as 
 54
appropriate. Wilcoxon test or Kruskal-Wallis test was used when comparing related 
samples. A two-tailed p-value of <0.05 was considered significant. 
Bivariate correlations were assessed using Spearman’s rank correlation due to the 
markedly skewed distributions. Multiple linear regression analyses were performed in 
Paper 2 and 4, using a backward variable elimination procedure. Receiver operating 
characteristics was used in Paper 3.  
For statistical analyses, the statistical software programs SPSS versions 23 and 24, 
GraphPad Prism 7 and R were used.  
7.8 Sample size and power analysis  
We aimed to include about 100 subjects in the hypothesis generating pilot study 
(NEEDED 2013). This would be comparable to similar studies on marathon runners 
(167,168). The pilot study focused mainly on kinetic and magnitude of cardiac 
biomarkers. CCTA in this cohort was obtained in subjects with the highest cTnI 
following the race, and was not a primary aim of this study. An overall 
methodological aim of the pilot study was to assess how many subjects it would be 
feasible to assess the following year, for the main study.   
The NEEDED 2014 study was designed to answer several research questions, of 
which the most important was considered to be the follow-up studies to assess long-
term consequences of exercise-induced cardiac biomarker increase. As such, we 
wanted the largest possible cohort, as CV events among healthy middle-aged subjects 
are rare. Based on the experience from the pilot-study, we did not consider it feasible 
to assess more than 1000-1100 subjects, even when omitting one sampling time-point 
following the race. Due to the large number of subjects who dropped out during the 
pilot study recruitment, we chose to close the inclusion after 1250 subjects had 
registered for the study. In total, 1002 subjects were included. These subjects will be 
followed at 5, -10 and 20 years for a primary endpoint of all-cause death, myocardial 
infarction, revascularization, sudden cardiac arrest, stroke and heart failure 
admissions. Cardiac arrhythmias and cancer in this cohort will also be assessed.  
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As a subgroup analysis, the 80 subjects with the highest cTnI increase following the 
2014 race were examined by CCTA (Paper 3). This was based upon findings from the 
pilot study. As an amendment to the protocol, 40 subjects with moderately elevated 
cTn were also examined by CCTA to determine to prevalence of CAD in this group. 
No similar studies had been published, and as such, there was insufficient data to 
perform adequate sample size and power calculations calculation in order to assess 
difference in prevalence of CAD in the High-cTnI vs the Reference group. Based on 
findings in the pilot study, three subjects in the High-cTnI group (cTnI > 201, 3/8) 
had significant coronary pathology; however, only two had obstructive CAD. If we 
considered the prevalence of CAD in the pilot study (25-37.5 % in the High-cTnI 
group), and assumed a prevalence of 5 % in the Reference group, a sample size of 40 





8. Ethical considerations 
This study has been approved by the Regional Ethic Committee (2013/550/REK 
vest). Study subjects were recruited among the participants in the North Sea Race, 
and all participants signed informed consent prior to enrollment. No specific 
subgroup was recruited. All participants voluntarily subjected to blood sample 
acquisition three times (four times in the pilot study). Participants with atypical 
findings, either on the ECG or due to blood sample analysis, were referred for further 
testing. Subjects included into the CCTA sub-studies were subjected to some 
radiation. The risks of this study were considered reasonable weighed against 
potential benefits.  
Data was collected and stored on secure servers of the Research Department of 
Stavanger University Hospital. Paper produced during data acquisition (ECGs, 
consent forms etc.) are stored in locked archives in the basement of “Forskningens 
Hus”, Stavanger University Hospital. Blood samples are stored in the local biobank at 
Stavanger University Hospital, in accordance with current standards. 
The athlete’s perspective on this study was important to us. One week following the 
NEEDED 2014 study, a follow-up questionnaire was collected. Subjects were invited 
to give their feedback, and were also asked about their motivation to participate. A 
total of 88.3 % of the study participants agreed or strongly agreed that contribution to 
increased understanding of exercise physiology was an important motivational factor 
(Figure 6). Of note, 71.6 % of the participants agreed or strongly agreed that a 
thorough health screening was of importance to them. This is of cause of importance 
when interpreting the results of this study, in relation to possible selection bias.     
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Figure 6: Participants motivation for participating in the NEEDED 2014 study.  
 
The main ethical consideration encountered during the work with this project related 
to findings of CAC and even CAD in otherwise healthy subjects.  
Subjects with obstructive and non-obstructive CAD were advised to start statin 
therapy (IA recommendation for patients with stable CAD) (165). This decision 
warranted discussion for several reasons; first, statin therapy to subjects with 
established CAD is clearly beneficial on a community level, however, could this 
evidence be readily transferred to otherwise healthy, highly active recreational 
athletes, some with very small plaques and low CAC score? Second, could we 
potentially risk an increased incidence of adverse effects of statins, and in particular 
rhabdomyolysis, in our cohort, based on the high activity level? Some case reports 
suggest that statin-users might be vulnerable to exercise-induced rhabdomyolysis 
(169-171). Third, would this treatment of a subgroup of our subjects affect the results 
of the long-term follow-up studies, and as such obscure important outcomes? We 
concluded that it was in the best interest of the individual participants with coronary 
atherosclerosis to be prescribed a statin, and considerations of possible adverse events 
and study outcomes were secondary concerns.  
For subjects without CVD, antiplatelet therapy is not indicated (III B 
recommendation) (164). However, there is a 1A recommendation for low-dose 
aspirin therapy for subjects with stable CAD in the 2013 guidelines on stable CAD 
(165). The WHO defines CVD as “… disease of the blood vessels supplying the heart 
muscle” (172). As such, a subject with a non-obstructive plaque probably falls within 
the definition of CVD. Stable CAD is defined in the 2013 ESC guidelines as 
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“episodes of reversible myocardial demand/supply mismatch, related to ischemia or 
hypoxia, which are usually inducible by exercise, emotion or other stress and 
reproducible – but, which may also be occurring spontaneously” (165). The 
guidelines then list four different underlying mechanisms of stable CAD: 1) Plaque-
related obstruction of epicardial arteries, 2) focal of diffuse spasm of normal or 
plaque-diseased arteries, 3) microvascular dysfunction and 4) left ventricular 
dysfunction caused by prior acute myocardial necrosis and/or hibernation (165). As 
such, our subjects with non-obstructive coronary plaques and no symptoms of angina 
might not fulfill the definition of stable CAD. In the new 2019 guideline on chronic 
coronary syndromes, aspirin therapy for subjects without a history of MI or 
revascularization, but with definitive evidence of CAD on imaging may be 
considered (IIb, C) (173). No references support this statement. For subjects with 
CAC > 100 Agatston Units, numbers needed to treat to prevent one cardiac event has 
been reported to be 173 for subjects with a Framingham risk score <10 %, and 92 for 
subjects with a Framingham risk score > 10 % (174).  
This 2013 recommendation of aspirin in subjects with stable CAD is based upon 
three studies; one is a randomized controlled trial published in 1992 and two are 
meta-analyses (published in 1994 and 2002) (165). In the randomized controlled trial, 
no tests of ischemia or angiography were required (175). Subjects below 30 years of 
age were not included. A 34 % relative reduction of MI and sudden death was noted 
among those who also received aspirin, p=0.003 (175).  
We found that the published studies were not readily transferable to our cohort of 
asymptomatic recreational athletes with non-obstructive plaques, and as such we 
were skeptical of advising aspirin therapy to these participants. Recent studies have 
also challenged the use of aspirin in primary prevention in subjects with CV risk 
factors (176-178). Subjects with obstructive CAD were advised to start aspirin 
therapy.    
The decision to refer subjects with obstructive CAD or highly increased coronary 
artery calcium score on CCTA to an invasive coronary angiography was made by the 
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project leader, in accordance with standard clinical practice at Stavanger University 
Hospital. The decision to revascularize some of these subjects was made by the 
invasive cardiologist responsible for the examination, in accordance with the patient. 
To date, however, the benefit of revascularization as an initial treatment approach of 
subjects with stable CAD, even for symptomatic subjects, is uncertain (179,180). 
Some of these subjects had very severe CAD, and wished to continue their level of 
physical activity, which probably influenced the decision to revascularize. Also, 
when asked in more detail, some did report atypical symptoms that could be 
interpreted as angina. Two subjects from the NEEDED 2014 study also had ECG 
changes following the race, which would support that ischemia was likely in these 
subjects (new T-wave inversions).  
Conflicts of interest have been disclosed by some of the co-authors on the Papers, 
mainly due to co-operation with Abbott and Roche. Furthermore, Dr. Bergseth is the 
Principal Medical Officer of the North Sea Race. None of the subjects with conflicts 
of interest participated in the data analysis of these studies.  
As researchers, we are ethically bound to share the results of our research to the study 
participants, fellow researchers and colleagues, as well as to the general population. 
The results of the NEEDED studies have been communicated to the study 
participants through the North Sea Race website, as well as in invited talks. The 
studies have also received coverage in both local, social and national media. The 
cardiology community has been well informed about the study, with presentations 
given at > 10 national and international congresses.   
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9. Results 
Paper 1 outlines the cardiac troponin I (cTnI) response after the North Sea Race in the 
97 subjects included in the pilot cohort. This paper also included data on CCTA on 
the 13 subjects with the highest cTnI response after the race. Paper 2 is an analysis of 
the predictors of the exercise-induced cTn response in the total NEEDED 2014 
cohort. Paper 3 outlines findings on CCTA in the 80 subjects with the highest cTnI 
after the race in 2014, and compares this with CCTA data from 40 subjects with 
moderate cTn increase. Paper 4 outlines the CRP response in the pilot cohort, and 
identifies the most important predictors of this response.   
9.1 Study populations 
Baseline characteristics of the 2013 (Paper 1 and 4) and 2014 cohorts (Paper 2) are 
outlined in Table 2. Paper 3 uses data on a subgroup of subjects from the NEEDED 
2014 cohort.  
Table 2: Excerpt of baseline characteristics of subjects included in the pilot study (NEEDED 2013, 
Paper 1 and 4) and in the main study (NEEDED 2014, Paper 2). 
 
 
 NEEDED 2013 (n=97) NEEDED 2014 (n=1002) 
Age, years 43±10 47 (40-53) 
Sex, male 74 (76) 782 (78) 
Body mass index, kg/m2 25.3 (23.4-28.0) 25.3 (23.7-27.3) 
Systolic blood pressure, mmHg 138 (129-152) 136 (126-148) 
Diastolic blood pressure 77 (71-85) 79 (73-86) 
Race duration, hours 4.2 (3.6-4.7) 3.7 (3.4-4.2) 
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Most of the included subjects were engaged in recreational sports only, and 25 % of 
the included subjects in 2014 exercised between 0-2 times per week (Figure 7). Study 
recruitment for Papers 2-3 is outlined in Figure 8. In total, 24 % of subjects ≥ 35 
years of age in the NEEDED 2014 had at least one CV risk factors, with BMI ≥ 28 
kg/m2 being the most prevalent (Figure 9).  
 
Figure 7: Exercise training experience in men (blue) and women (red) of the 2014 cohort: a) Highest 
level of competitive experience, b) Years of regular exercise training, c) Number of endurance 
exercise competitions past 5 years before the study, d) Self-reported MET hours per week, obtained 
by the International Physical Activity Questionnaire, e) Exercise sessions per week during spring of 















Figure 8: NEEDED 2014 study recruitment. Paper 2 includes an analysis of the 1002 
participants that were included in total. Paper 3 includes an analysis on the High-cTnI 
group vs Reference group subjects.  
 
 
Figure 9: Among the senior athletes (≥35 years of age) in the NEEDED 2014 cohort, 238 subjects 
had at least one CV risk factor.  
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9.2 Paper 1 
Cardiac troponin I (cTnI) increased from 3.4 (2.1-4.9) ng/L at baseline, to a maximal 
of 69 (42-98) ng/L at 3 hours after the race (Figure 10). None of the included subjects 















Figure 11: 13 subjects were assessed by CCTA or conventional coronary angiography in 
the NEEDED 13 study. Subject A had an obstructive lesion in the left anterior descending 
artery, and an occluded right coronary artery, subject B had obstructive coronary lesion in 




CCTA was obtained in the 13 subjects with the highest cTnI values following the 
race, and revealed obstructive coronary artery disease in two subjects (Subjects A and 
B), and a plaque rupture in one subject (Subject C, Figure 11). These three subjects 
were among the four with the highest cTnI values following the race. These findings 
suggested that subjects with subclinical coronary artery disease might have an 
excessive cTnI increase after strenuous exercise, as compared with subjects with no 
cardiac obstruction.  
9.3 Paper 2 
Distributions of cTnI and cTnT values at baseline, and at 3- and 24 hours after the 
race are shown in Figure 12. At 3 hours after the race, 84 % of subjects exceeded the 
99th percentile of the cTnI assay (26 ng/L), and 92 % of subjects exceeded the 99th 
percentile of the cTnT assay (14 ng/L). At 24 hours after the race 18 % (cTnI) and 30 
% (cTnT) still had values above the 99th percentile.  
In this study, bivariate and multiple regression models identified shorter race duration 
and higher systolic blood pressure at baseline as consistent significant predictors of 















Figure 12: Distribution of cTn at baseline, and at 3- and 24 hours after the race, red 
indicates female subjects; blue male subjects. Dotted lines represent the sex-specific 99th 
percentile).  
 66
9.4 Paper 3  
The 80 subjects with the highest cTnI values at either 3- or 24 hours after the race 
were examined by CCTA. A reference cohort of 40 subjects with moderately elevated 
cTnI after the race were also evaluated by CCTA. Baseline characteristics were 
similar between the two groups, with a mean age of 45±11 years in the High-cTnI 
group and 46±11 years in the Reference group.  
In total, 80 of the 120 subjects had normal coronary arteries, two had myocardial 
bridging, and 39 had CAD (one of whom also had a myocardial bridge, and as such, 
she is counted twice).  
Obstructive CAD was present in 8 subjects (10 %) in the High-cTnI group, and in one 
subject (2.5 %) of the Reference group. These 9 subjects had significantly higher cTn 
values at 24 hours after the race, but not at 3 hours after the race (Figure 13).  
 
Figure 13: Cardiac troponin I (cTnI) and cardiac troponin T (cTnT) concentrations in subjects assed 
by coronary computed tomography angiography (n=118). Green columns represent subjects without 
coronary artery obstruction (n=109). Blue bars represent subjects with obstructive coronary artery 
disease (CAD, n=9). The two subjects with myocardial bridging are not included. The dotted 
horizontal line represents the 99th percentile of each assay. 
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9.5 Paper 4 
C-reactive protein (CRP) increased from 0.9 (0.5-1.8) mg/L at baseline to 11.6 (6.0-
17.5) mg/L at 24 hours after the race (p<0.001). In this study, a significant association 
with physical fitness and the exercise-induced CRP response was identified, 
independent of age, sex and body mass index (BMI, Figure 14). A significant 
association with CRP 24 hours after the race and creatine kinase, a marker of 
muscular injury, was also identified.  
 
 
Figure 14: Mean CRP levels before, immediately after the race, 3 hours after the race and 
24 hours after the race in subjects with different fitness levels. A: Subjects are parted into 
quartiles base don race duration from fastest to slowest, B: Subjects are parted into 
quartiles based upon hours of training per week the 3 months leading up to the race, C: 
Subjects are parted into quartiles based upon number of previously completed races over 
the past 5 years, D: self-reported fitness (1: Very good, 2: good, 3: average, 4: below 




There was no association between the exercise-induced CRP, cTnI and B-type 
natriuretic peptide response following the race. Also, no association between 





Cardiac troponins are sensitive markers of myocardial injury. C-reactive protein is a 
marker of global inflammation. Both markers are strongly associated with future CV 
events, and both markers increase following exercise. In this thesis, the physiological 
cTn and CRP increase is described. For a subset of subjects with underlying 
obstructive CAD, a potential pathological cTn increase was identified.   
10.1 Underlying mechanisms of exercise-induced cTn 
increase 
Cardiac troponins increase due to necrosis of cardiomyocytes. Other mechanisms of 
cTn increase, i.e. apoptosis or cell wounds, are still poorly understood, particularly in 
the setting of exercise.  
Necrosis of cardiomyocytes is an unlikely explanation for exercise-induced cTn 
increase due to the low regeneration rate of cardiomyocytes in humans, and the 
frequency in which cTn increase with exercise is described (116). This is supported 
by mechanistic data by Weil et al., who found that an increase in preload was 
associated with a transient cTn increase in the absence of ischaemia (181). It has been 
suggested that exercise-induced cTn increase due to leakage of loosely bound 
cytoplasmic cTn by blebbing or increased membrane permeability, however, more 
research in this area is needed in order to conclude on the underlying mechanisms of 
exercise-induced cTn increase (116,118). Studies on cTn fragments might be one 
such avenue in order to understand these underlying mechanisms. One small study 
found that cTnT only existed as secondary fragments in marathon runners (95). These 
findings need to be confirmed in larger cohorts, however, there are still analytical 
difficulties with these methods.  
The Papers in this thesis have not directly explored the underlying mechanisms of 
exercise-induced cTn increase. The high prevalence of cTn increase above the 99th 
percentile of the assays that was found in Paper 2, however, underscores the 
unlikeliness of necrosis as the primary mechanism of exercise-induced cTn increase 
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in the majority of participants. Further work on cTn characterisation of the NEEDED 
samples is currently ongoing.  
10.2 Kinetics of exercise-induced cTn 
Several studies have sampled cTn several times following exercise to describe the 
cTn kinetics. The landmark study by Middleton et al. studied the kinetics of cTnT 
release in relation to a marathon in 9 subjects. In this study, a biphasic cTnT release 
was noted, with the first peak during the marathon, and the second peak at 6-24 hours 
after the marathon (124). According to a review article by Gresslien et al. there is 
evidence to support a peak in cTnT at 2-5 hours post-exercise, and a peak in cTnI at 
3-6 hours post-exercise (116). The underlying evidence of this statement, however, is 
rather weak, and based primarily on very small and selected cohorts. None of the 
citations for this statement included studies solely on cycling events.   
Scherr et al. sampled cTnT prior to a marathon, and immediately- , 24 hours- and 72 
hours after the marathon (168). They found a peak in cTnT immediately after the 
race, however, with no sampling between 0-24 hours post-race, this study did not 
provide a definite time of peak for exercise-induced cTnT elevation (168). The study 
by Herrmann et al. included 46 marathon runners, and sampled cTnI and cTnT at 
baseline, and at 15 minutes and 3 hours post-race (123). They found that cTn 
continued to increase from 15 minutes post-race to 3 hours post-race in most subjects, 
supporting the statement by Gresslien et al (116). Similar findings were presented by 
Sharhag et al., who also included a subgroup of cyclists (122).  
At the time we designed the NEEDED study, there was scarce evidence on the 
expected kinetics of cTn in relation to exercise in general, and to prolonged cycling in 
particular. In paper 1, we confirmed that cTnI was higher at 3 hours post-exercise 
than immediately after exercise. The cTnI levels had not completely normalized 
within 24 hours following the race. Due to logistical challenges, adding more 
sampling time-points to the protocol was not feasible. Additional sampling time 
points would have added valuable information about the best time of sampling for 
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peak cTnI. To achieve the best degree of comparability between the pilot-study and 
the main study (NEEDED 2014, papers 2-3), the same time-point of 3 hours post-race 
was used for the main study.  
10.3 Predictors of exercise-induced cTn elevation  
Gresslien et al. reviewed the literature concerning cTn increase and exercise between 
1987 and 2015, and included a total of 145 studies (116). There are several 
methodological difficulties in comparing these 145 studies, particularly due to the use 
of different cTn assays, and different protocols of cTn sampling. Most of these 
studies only sampled cTn immediately after exercise, and many only included male 
subjects. Also, only 8 of these studies included more than 100 subjects (117,168,182-
187).  
Of these 8 larger studies of > 100 included subjects, two were performed on low-
intensity or duration exercise (184,187), and might therefore not be fully comparable 
to the other 6, which were conducted on 21-42 km running events 
(117,168,182,183,185,186). Fortescue et al. (n=482) was the largest investigation 
prior to the NEEDED study, and was the only one of the 8 studies of > 100 subjects 
which studied both cTnI and cTnT. This study, however, only sampled cTn before 
and immediately following a marathon. Also, data collection was performed in 2002, 
and older cTn assays were used. In statistical analyses, subjects were assessed as 
above or below the 99th percentile cut-off, and the authors found that runners with 
troponin increase were younger, and more likely to be women. Runners with no prior 
marathon experience were also more likely to have a post-race cTn above the cut-off. 
Shalen et al. used very similar methodology, and they also found that no prior race 
experience was associated with cTn increase above the 99th percentile, but in contrast, 
they also identified higher age and creatinine increase as predictors in their analysis 
(185). Jassal et al. assessed cTn shortly after a marathon, and concluded that less 
running experience was associated with higher cTn values (183). Mingels et al. found 
that a longer running distance was associated with higher cTn increase (187).   
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Scherr et al. is the largest study prior to the NEEDED study which presented a linear 
regression analysis to determine the predictors of the exercise-induced cTn. They 
only presented data on cTnT increase from baseline to immediately after the race, but 
found that higher IL-6, lower age, higher body fat and higher increase in h-fatty acid 
binding protein were associated with the cTnT increase (R2=0.29). The study by 
Eijsvogels et al. on prolonged walking also presented a linear regression analysis, and 
found that higher age, CV pathology and walking speed were significant predictors of 
cTn elevation (R2=0.11) (184).  
Another slightly smaller study by Eijsvogels et al. assessed predictors of the cTn 
release immediately after a marathon in a subgroup of 67 athletes. They found that 
lower age and longer exercise duration were significant predictors (R2=0.093) (188). 
Mingels et al. included 85 subjects and also sampled immediately after the race (167). 
In their multiple regression analysis, higher age and lower running experience were 
significant predictors. The largest study on exercise-induced cTn in relation to 
cycling (n=91) also sampled cTnI immediately after the race (189). This study only 
presented bivariate correlations between different predictors and cTn (189).  
The studies by Scherr et al., Eijsvogels et al., and Mingels et al., are some of the 
studies who presents the most reliable data on predictors of the exercise-induced cTn 
increase, however, they are all limited by sampling at a time where cTn is expected to 
continue to increase, and by their relative low number of included subjects 
(167,168,188). The three studies also did not include the same variables into their 
models. Two of them found that age was inversely associated with increased 
exercise-induced cTn (168,188), while one study found a positive association (167). 
Most of the presented studies agree that less training experience is also associated 
with a higher degree of cTn increase post-exercise.  
Paper 2 in this thesis details the conflicting evidence surrounding different variables 
that are believed to be associated with the exercise-induced cTn increase. In this 
paper, comprehensive multiple regression analyses are presented for the largest 
cohort to date (n=1002). Our findings are presented at baseline, 3 hours- and 24 hours 
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post-race, and for both cTnI and cTnT. Multiple regression analyses are also 
presented for delta cTn values in the Supplementary Appendix, with very similar 
results as presented in the manuscript.  
Contrary to other studies, we found that the major predictors of exercise-induced cTn 
increase were lower race duration and higher systolic blood pressure. It is important 
to note that systolic blood pressure was not included into several of the linear 
regression models in the previous studies (167,168,188).   
Age was not a consistent predictor in the multiple regression models. Also, training 
experience was not found to be significantly associated with the cTn increase. In fact, 
one could argue that subjects who are able to finish the race faster have a higher 
physical fitness level than subjects who cycled slower. This is supported by the 
findings in Paper 4, where there were good correlations between race duration, self-
reported physical fitness, number of previous competitions over the past 5 years and 
exercise volume prior to the race. Race duration, however, also reflects technical 
skills and exercise intensity, which needs to be considered when interpreting this 
parameter. Subjects with low race duration might have spent a large percentage of the 
race at a very high intensity level. High intensity work and increased peripheral 
resistance (systolic blood pressure) are both parameters that reflect cardiac work load.  
Body composition has been evaluated in several prior studies, and in a meta-
regression analysis, body weight was positively correlated with increased exercise-
induced cTn levels (125,190). In our study, however, body composition had 
inconsistent correlations with the exercise-induced cTn increase. Other CV risk 
factors, like cholesterol levels, family history of premature CV disease or the 
Framingham Risk Score was also not significantly associated with the exercise-
induced cTn increase. Subjects with at least one CV risk factor did, however, have 
slightly higher cTn levels 24 hours post-race as compared with subjects with no risk 
factors (p<0.01).  
Paper 2 of this thesis provides important and novel insight into the clinical variables 
that are associated with exercise-induced cTn increase. It is important to note the low 
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coefficient of variance for these models. This suggests that unknown factors are of 
major importance in this process, and further research is needed.  
10.4 Cardiovascular disease in the NEEDED 2014 cohort 
In the NEEDED 2013 cohort, only a limited number of subjects were assessed by 
CCTA. In the NEEDED 2014 study, however, 120 subjects were examined by 
CCTA. A median CAC score of 0 (0-3) Agatston Units was found for this cohort 
(n=119, one subject in the High-cTnI group was only assessed by invasive coronary 
angiography). The CAC scores in this cohort were in line with the study by Merghani 
et al. (39) and by findings from population-based cohorts (191,192), but lower than 
that found by Aengevaeren et al., Möhlenkamp et al., and Braber et al (43,50,51). 
Only 29 % of the 119 subjects assessed by CCTA in Paper 3 had CAC > 0 Agatston 
Units (males: 33 %, females: 19 %), which is also lower than in the previous studies 
on recreational athletes. One major reason for the lower prevalence of CAC in our 
cohort is that the mean age was 45±11 years, contrasting a mean age of 54-57 years 
in previous studies (39,43,50,51). Also, 26 % of the present cohort were female.  
CAC is an indicator of the burden of coronary artery atherosclerosis. CAC, however, 
lacks the ability to identify luminal stenosis and vulnerable plaques, i.e. plaques with 
large necrotic cores, and macrophage infiltration in the fibrous cap. Having CAD on 
CCTA has been found to significantly increase the risk of future CV events (193). 
Subjects with obstructive lesions (>50 % stenosis) have a higher risk of CV events 
than subjects with non-obstructive lesions (193,194). Subjects with non-obstructive 
lesions, however, still have a 3-year risk of 1.3-3.7 % of major adverse cardiac events 
(166,194). Since most findings on CCTA are of a non-obstructive nature, this group 
is of importance when trying to prevent future CV events. Using CCTA and plaque 
characterization, Hou et al. found that patients with calcified plaques only had less 
clinical events than subjects with non-calcified or mixed plaques, suggesting that 
calcified plaques are a more stable form of CAD (194).  
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Nine subjects (7.5 %) in the NEEDED 2014 CCTA cohort had obstructive CAD. 
Braber et al. found that 5.3 % of sportsmen in their cohort had obstructive lesions 
(50). Merghani et al. reported a 3.3 % prevalence of luminal stenosis > 50 % in their 
cohort of male and female athletes (39). Mölenkamp et al., and Aengevaeren et al. did 
not report CCTA data (43,51). Mean age of study subjects in the studies by Braber et 
al. and Merghani et al. were 55 years, contrasting our cohort with a median age of 45 
years of age (39,50). As such, there was a higher prevalence of obstructive CAD in 
our cohort as compared to these two studies, even with a markedly lower mean age of 
study subjects and inclusion of female subjects in our cohort. It is likely that this 
reflects selection of study subjects. The most striking difference in selection of study 
subjects between NEEDED 2014 study (Paper 3) and Braber et al. and Merghani et 
al., is that 66 % of our subjects were selected based on highly increased exercise-
induced cTnI. Eight of the nine subjects (89 %) with obstructive CAD were identified 
within the High-cTnI group.  
10.5 Cardiac troponins and cardiovascular disease 
Increased levels of cTn has been associated with worse outcomes in population based 
studies (112,113), as well as for subjects with CVD (195), arrhythmias (78), non-
cardiac surgery (80), end-stage renal disease (76) and stroke (79). The long-term 
outcomes of subjects with exercise-induced cTn have been evaluated in two studies, 
both published after the initiation of the NEEDED project. Möhlenkamp et al. found 
no association between CVD and exercise-induced cTnI in 74 marathon runners (82). 
In contrast, Aengevaeren et al. (n=725) found a highly significant association 
between exercise-induced cTnI above the upper reference limit and CV events in 
their cohort of older subjects performing 30-55 km of walking (83).  
Since there seems to be an association between cTn and future CVD in population-
based studies, an association between cTn and the degree of CAD is expected. This 
was assessed by Reckord et al., who found higher cTn concentrations in subjects with 
more severe CAD on CCTA (196). A small study by Rusnak et al. also found that 
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subjects with mixed plaques had higher cTn levels than subjects with no CAD or with 
calcified or non-calcified plaques (197).  
10.6 Obstructive coronary artery disease in relation to 
exercise-induced cTn increase 
In Paper 1, obstructive CAD was identified in two subjects, while one subject had a 
plaque rupture. In Paper 3, nine subjects had obstructive CAD. Subjects with 
obstructive CAD had significantly higher cTnI and cTnT levels 24 hours after the 
race, as compared with subjects with normal coronary arteries or non-obstructive 
CAD (cTnI: 151 (72-232) vs 36 (19-82) ng/L, p=0.005, cTnT: 39 (35-55) vs 20 (14-
31) ng/L, p=0.002). cTn was found to be able to discriminate the subjects with 
obstructive CAD from the rest of the cohort, with AUC of 0.79 (95 % CI: 0.61-0.96), 
p=0.005 for cTnI and 0.82 (0.70-0.94), p=0.002 for cTnT (Paper 3).  
The difference in cTn kinetics between subjects with obstructive CAD and subjects 
without coronary obstruction could be related to demand ischaemia and a degree of 
cardiomyocytes necrosis. As described in chapter 10.3, physiological exercise-
induced cTn tends to peak at 2-6 hours post-exercise, and then normalize at 24-72 
hours post-exercise. This contrasts the later rise in cTn levels seen following 
myocardial infarction, where there is a release of structural cTn due to cellular 
necrosis (100). This hypothesis, however, is difficult to prove with certainty, and 
more research is needed.  
Subject C in Paper 3 had a cTnI profile of 1.7 ng/L-28 ng/L-8 ng/L. This subject was 
a Reference group subjects who had an obstructive lesion in the left anterior 
descending artery with an FFR of 0.78, obtained almost a year after the race. We 
cannot be certain that this subject had an obstructive lesion at the time of cTn 
sampling. Subject I also had a cTnI profile that might be lower than expected with a 
90 % obstruction of the LAD (1.6 ng/L-263 ng/L-41 ng/L). This subject was a 66-
year old female who used 4.9 hours to finish the race (above the 75th percentile for 
the entire cohort of the NEEDED 2014 study). The present study did not mandate the 
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use of heart rate monitors to assess work during the race, and as such, we cannot be 
certain that this subject performed sufficient high-intensity work during the race to 
induce demand ischaemia. The exact association between cardiac work and cTn 
increase needs further research. Also, as described in chapter 10.4, there are large 
individual differences in exercise-induced cTn not accounted for by commonly used 
clinical parameters.  
There was no statistically significant difference in prevalence of obstructive CAD 
between the High-cTnI group and the Reference group. The study was underpowered 
to prove a difference at the observed level. When the prevalence of obstructive CAD 
in the Reference group (2.5%) was extrapolated to the cohort of subjects where 
CCTA was not obtained (n=882), a highly significant difference between the High-
cTn group and the rest of the cohort was observed (OR 4.28 [1.85-9.87], p=0.002). 
However, we cannot be certain that the prevalence of obstructive CAD in the 
Reference group reflects the true prevalence in the remaining subjects with a low or 
moderately elevated cTn following the race. We therefor chose to omit this finding 
from the manuscript.  
Paper 3 is the first study to demonstrate exercise-induced cTn levels in subgroups of 
patients with normal coronary arteries, non-obstructive CAD and obstructive CAD. 
The findings suggest a potential role of exercise-induced cTn in determining if an 
athlete has physiological or potentially pathological response to exercise, however, 
more research is needed to confirm and extend these findings to different cohorts.  
10.7 Non-obstructive CAD in relation to exercise-induced 
cTn increase 
CV events in subjects with vulnerable, non-obstructive plaques are prevalent (198). 
The association between non-obstructive plaques and exercise-induced cTn increase, 
however, is uncertain. Möhlenkamp et al. and Paana et al. found no association 
between CAC score and cTn obtained immediately following a marathon (82,199). 
This non-significant association between CAC and cTn at 3- and 24 hours was 
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confirmed in our material. Also, subjects with non-obstructive CAD did not have 
higher cTn levels as compared with subjects with normal coronary arteries (Table 3). 
The combined analysis of the CCTA findings from the NEEDED 2013 and 2014 
cohorts (Paper 1 and 3) were presented at EuroPrevent 2019 (200). In this 
presentation, plaque morphology was assessed, and among the 30 subjects with non-
obstructive CAD, 20 (67 %) had calcified plaques only. There was no significant 
difference in cTn kinetics among subjects with non-calcified or mixed plaques as 
compared to subjects with calcified plaques only. These findings support the 
hypothesis that a supply-demand mismatch is important for generating a prolonged 
elevation of exercise-induced cTn, as seen for subjects with obstructive CAD.  
High-risk plaques features include low attenuation (0-30 Hounsfield Units), positive 
remodelling and the Glagov phenomenon, as well as plaques with spotty 
calcification/napkin ring sign (201). These plaque features have not yet been analysed 
within the NEEDED cohort.  
Table 3 cTnI and cTnT in participants from the combined CCTA examinations from the 2013 and 
2014 studies (n=133). Values are presented as median (25th-75th percentile), or as mean (minimum-







bridging (n=2)  
Obstructive CAD 
(n=11) 
cTnI baseline, ng/L 2.3 (2-6) 3.7 (2-7) 7.0 (6-8) 2.8 (2-7) 
cTnI +3h, ng/L 224 (150-303) 182 (76-257) 772 (443-1002) 269 (206-808) 





cTnT baseline, ng/L 3.0 (3-5) 3.3 (3-5) 3.5 (3-4) 4.5 (3-10) 
cTnT +3h, ng/L 85 (60-123) 84 (38-124) 220 (115-325) 100 (59-140) 
cTnT +24h, ng/L 21 (14-34) 23 (13-29) 43 (31-54) 44 (38-75) 
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10.8 Myocardial bridging in relation to exercise-induced 
cTn increase 
Two subjects, both in the High-cTnI group, had myocardial bridging on CCTA. Their 
characteristics are outlined in Paper 3. As shown in Table 4, both of these subjects 
had lesions located in the mid left anterior descending artery (LAD). Myocardial 
bridging with a depth of ≥1 mm might be considered deep (202).   
Table 4: Characteristics of the two subjects with myocardial bridging. LAD=Left anterior 
descending artery.  
 Age (years) Sex Localization Length (mm) Depth (mm) 
Subject A 27 Male LAD, segment 7 20 4 
Subject B 55 Female LAD, segment 6 25  3 
 
Myocardial bridging is an intramural course of an epicardial coronary artery. In 
systole, myocardial bridges might compress blood flow through the tunnelled artery. 
However, under normal circumstances, approximately 85 % of the coronary blood 
flow occurs during diastole (203). It is also a very common finding on CCTA, with 
Dimitriu-Leen et al. reporting that 22 % of low- and intermediate risk subjects who 
were referred to a CCTA had some degree of myocardial bridging (204). A review on 
this topic concluded that approximately one in four have a myocardial bridge (203). 
The frequency and underlying understanding of the coronary blood flow suggest that 
a myocardial bridge is a physiological phenomenon in most cases. This is also 
supported by long-term follow-up studies who did not find that myocardial bridging 
was associated with worse cardiac outcomes (204,205).  
Both of our study subjects were asymptomatic during and after the race, and had no 
findings suggestive of ischaemia on ECG. We decided not to do further testing or 
follow-up procedures for these two subjects (other than for all the NEEDED study 
subjects). The current ESC sport cardiology recommendations states that the presence 
of exercise-induced ischaemia or complex ventricular tachyarrhythmias in subjects 
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with a myocardial bridge should warrant restriction from participation in competitive 
sport (level of recommendation: Class IIa, level of evidence C) (206). As such, a 
maximal exercise test might be indicated in these subjects. A study by Kramer et al. 
from 1982, however, only identified a positive stress test in 3/25 symptomatic 
subjects with myocardial bridging identified by coronary angiography (207). The best 
functional assessment of a myocardial bridge is probably a diastolic fractional flow 
reserve with the use of dobutamine challenge (203). This is an invasive procedure, 
which, in our opinion, would not influence the clinical decision-making for these 
asymptomatic subjects. Our decision is supported by a flow-chart on management of 
myocardial bridging of the left anterior descending artery proposed by Tarantini et al 
(203).  
Interestingly, subject B also had non-obstructive CAD. Coronary artery plaques are a 
common finding in subjects with myocardial bridging, most likely due to high 
systolic wall shear stress upstream from the bridge (203). Subject B, however, had a 
non-calcified plaque in her right coronary artery, and the area proximal to the 
myocardial bridge was not affected.  
There is limited knowledge on the consequences of myocardial bridging and the risk 
of sport-related cardiac events. Exercise-induced premature ventricular complexes 
and non-sustained ventricular arrhythmias have also been described to be more 
frequent in subjects with myocardial bridging (208), as well as case-reports of 
myocardial infarction and sudden death (209). It is interesting that both of our 
subjects had highly elevated cTn following the race, and this might suggest a supply-
demand mismatch in these individuals. It is important to acknowledge, though, that 
cTn elevation does not equal ischaemia, and several other subjects with no 
myocardial bridge had similarly elevated cTn following the race. Importantly, no 
adverse clinical events have been identified for these two individuals since the 2014 
race.      
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10.9 Exercise-induced CRP increase 
Prior to the NEEDED study, there was uncertainty about the kinetics of exercise-
induced CRP, the magnitude of the CRP increase and the predictors of this response. 
The clinical significance of the exercise-induced CRP response was also unknown. 
We addressed these topics in Paper 4, and found an 129 % increase in CRP levels 24 
hours following the North Sea Race, as compared to baseline levels, p<0.001. The 
magnitude was less than described following marathon-running by Weight et al., 
(155), but similar as described by Sherr et al. (168). We did not sample after 24 hours 
following exercise, however, other studies have confirmed that exercise-induced CRP 
levels decrease at 48-72 hours following strenuous exercise (168,210,211).  
In bivariate and multiple regression analyses, physical fitness was significantly 
inversely associated with the magnitude of the CRP response, assessed as race 
duration, self-reported fitness level, number of prior endurance exercise competitions 
during the past 5 years and number of hours per week of endurance exercise training. 
The present study did not use peak oxygen consumption to determine physical 
fitness; however, all measures of physical fitness were well correlated with each 
other.  
The correlation between physical fitness and exercise-induced CRP increase might 
have been anticipated, as less fit subjects have smaller cardiac dimensions, less 
developed musculature and vasculature and a lower degree of exercise efficiency as 
compared with highly trained athletes. During acute exercise, contracting viable (i.e. 
non-damaged) skeletal muscle serve as a secretory organ, secreting pleiotropic 
molecules collectively called myokines which exerts paracrine and endocrine effects 
on various target organs. During and shortly following physical activity, IL-6 is 
released from myocytes causing plasma levels to increase hundred-fold compared 
with baseline values (153,154). IL-6 serves as an upstream regulator of CRP 
production in the liver, and Scharhag et al. showed that exercise-induced CRP and 
IL-6 were strongly correlated (R=0.68, p<0.001) (212). This association between 
muscle metabolism and inflammation might also be the reason why an association 
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between exercise-induced CRP and CK was identified. The correlation between 
exercise-induced CRP and CK is in line with findings by Strachan et al. (210).  
Findings from the present study confirms and extends on prior findings. Liesen et al. 
found an attenuation of the exercise-induced CRP response following 9 weeks of 
endurance training; however, this study only included three male subjects (213). 
Mündermann et al. (n=45) described a relationship between marathon performance 
and exercise-induced CRP, however they included male subjects only (214). The 
findings of the present study suggest that the beneficial effects of high degree of 
physical fitness might not only relate to a favourable modulation of basal 
inflammation, but also an improved biological response to physical stress. 
There are known associations between baseline CV risk factors and CRP, and as 
such, the influence of CV risk factors on exercise-induced CRP was assessed in 
multiple regression analysis. At baseline, BMI was significantly associated with the 
CRP level of the present cohort. The association between BMI and exercise-induced 
CRP levels, however, was not significant in the present study. This is in line with 
findings by Mündermann et al. who also did not find an association between BMI and 
exercise-induced CRP (214). We wanted to assess the relationship between CV risk 
factors and the exercise-induced CRP response further in the 2014 cohort in order to 
confirm this finding, however, in this larger cohort, BMI was significantly associated 
with exercise-induced CRP increase (Figure 15) (215). Baseline LDL levels also had 
a significant bivariate correlation with exercise-induced CRP in the 2014 cohort 
(rho=0.12, p<0.001). Systolic blood pressure was not associated with exercise-
induced CRP increase. As such, it is important to note that in small studies, and 
particularly studies with homogenous cohorts, certain associations are difficult to 
assess with certainty.  
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Figure 15: The association between BMI, race duration and the CRP increase during the NEEDED 
2014 study (n=1002) (215).  
A secondary aim of Paper 4 was to evaluate the association between the exercise-
induced CRP, cTnI and BNP after strenuous exercise. No significant relationship was 
observed. This is in line with findings by Scherr et al., who also did not find an 
association between CRP and cTnT following a marathon (168). They, however, did 
not sample cTnT at the expected peak at 2-6 hours following exercise (168). 
Scharhag et al. assessed the association between CRP and N terminal pro brain 
natriuretic peptide (NT-proBNP) (212). They found no association between exercise-
induced CRP and NT-proBNP levels in their cohort of 14 athletes, suggesting that the 
exercise-induced increase in NT-proBNP was unrelated to inflammation (212).  
In order to assess the significance of the exercise-induced CRP increase, data on 
infections and well-being at 1-week post-race was collected. Clinical events 
following the NEEDED 2013 study were defined as self-reported unscheduled 
healthcare contact (n=3), sick leave or unusual discomfort 1 week following the race 
(n=9). These subjects had non-significantly increased levels of CRP both prior to the 
race and 24 hours following the race. These findings are reassuring; however, the 
small sample-size of this study prevents us to conclude with certainty on the clinical 
significance of exercise-induced CRP. The association between exercise-induced 
CRP increase and clinical end events will be further assessed in the 5-year follow-up 
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study of the NEEDED 2014 cohort, where the primary end-pint is a composite of 
mortality, myocardial infarction, revascularization, sudden cardiac arrest, heart failure 
and stroke.       
10.10 Other exercise-induced biomarkers 
The NEEDED study program measured several cardiac biomarkers. In Paper 1, the 
kinetics of creatine kinase – myocardial band (CK-MB), creatine kinase (CK), B-type 
natriuretic peptide (BNP) and creatinine are outlined, all of whom increased 
significantly from baseline (p<0.0001). We also assessed copeptin in the pilot cohort, 
and did not find an association between the exercise-induced copeptin-response and 
the subjects with CAD (216). Lastly, we have several other manuscripts currently 
under construction or consideration, most notably one on exercise-induced changes in 
lipoproteins, and one on 4-year follow-up of CCTA indices.  
10.11 Clinical implications and future perspectives 
Endurance exercise training is highly beneficial for good health. High-intensity 
exercise, however, does carry a small risk of sudden cardiac arrest. Prior research has 
focused on pre-participation evaluation of athletes in order to determine if a subject it 
at risk of a sport-related cardiac event. The NEEDED project explores to role of 
exercise-induced cardiac biomarkers in determining if certain subjects might have a 
pathological response to exercise, and thereby be at higher risk of future CV events.  
Findings from the NEEDED studies are novel in several aspects, particularly due to 
the use of CCTA in assessing the relationship between CAD and exercise-induced 
cardiac biomarkers. This is the first study to show that exercise-induced cTn has a 
prolonged elevation in subjects with occult obstructive CAD, discriminating these 
subjects from subjects with no coronary obstruction. As such, this finding could 
potentially lead to the use of post-exercise cTn measurements to identify subjects at 
risk of a cardiac event. However, the data presented thus far is cross-sectional of 
nature, and is only valid for this cohort of recreational athletes. Our findings need to 
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be confirmed in other cohorts, and the long-term clinical significance must be 
determined.  
The NEEDED study also shows that measuring cTn immediately following exercise 
is insufficient, and that later sampling is necessary to detect peak cTn and to find a 
difference between subjects with potentially clinical relevant CAD. This is of 
importance for future studies of similar design.    
The overall aim of the NEEDED project is to assess long-term CV health in 
recreational athletes. As such, follow-up data will be collected at 5-, 10- and 20 years 
after the NEEDED 2014 study.  
Several avenues of research are ongoing within the NEEDED research program. 
First, characterization of cTn molecules is one area of interest that might increase the 
understanding of the underlying mechanisms of cTn release in relation to exercise. 
Second, data regarding the 5-year risk associated with the exercise-induced increase 
in cardiac biomarkers is currently being collected and analysed. Third, there is still a 
high degree of uncertainty about the association between cardiac work and exercise-
induced cTn increase. This is being assessed as part of the physiological NEEDED 
2018 study (n=62). This study also included echocardiographic data on study 
participants before and after strenuous exercise, including strain analysis and three-
dimensional image acquisition. These data might increase our understanding of the 
association between cardiac function and exercise-induced cardiac biomarkers. Forth, 
exercise-induced changes in electrocardiograms are being analysed, and will provide 
us with further understanding of exercise-induced electrical changes in relation to 
cardiac biomarkers. Lastly, we have two projects planned, one on chronic cTn 
increase in Olympic athletes, and one on determining the threshold of exercise 
needed to induce a cTn increase. Further description of other cardiac biomarkers in 
relation to exercise will also be published.  
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10.12 General limitations 
The findings presented in this thesis are based on observational data, and subjects 
were recruited based on their participation in the North Sea Race. This generated a 
pool of study subjects that were predominantly male, and of Caucasian ethnicity. The 
included subjects were probably more physically active than the general population. 
Most of the included subjects, however, were not masters athletes, and we have used 
the term “recreational athlete” in order to describe the current study populations, the 
word that in our opinion most closely mimics the Norwegian term “mosjonist”.  
Other selection biases might also have affected the results, such as the interest in a 
comprehensive cardiac work-up, a motivational factor that was present in > 70 % of 
our study subjects (see chapter 8). Attrition bias should also be mentioned as a 
general limitation of this study, as several participants, both in the pilot and the main 
study, registered for the study, but did not complete the race or data sampling. These 
subjects were not included in the analyses.  
The quality of data collection was generally very high, with trained nurses and 
bioengineers performing most of the procedures. The physiological parameters that 
were obtained several times were generally very well correlated, with Spearman’s 
rank correlation coefficient > 0.9. However, with such a large data acquisition, there 
are likely to be some errors, both of a human nature and due to analytical difficulties 
with analysing > 3000 batches of blood in a 72-hour period. Blood samples that were 
found to be outliers underwent quality testing.  
In both the pilot study and the 2014 main study, blood samples were acquired at 
baseline and within 24 hours following the race. This precludes us from determining 
if later exercise-induced changes in cardiac biomarkers might be of importance. Also, 
due to the large sample-sizes, physiological data such as peak O2 and 
echocardiographic assessments were not collected. Questions or analysis to identify 
possible doping among our study subjects were also not included as part of the study 
protocol.  
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The protocol for the main study was based on findings from the pilot study, and 
reflects the evolution of knowledge during this project. As we did not have the 
resources to include all study subjects for a CCTA, we had to choose which 
participants to include for the CCTA sub-studies. In the main study, we chose to 
include the 80 subjects with the highest cTn at any time after the race. This decision 
was based the strong association between cTn increase and risk of CAD in a clinical 
setting, findings from the pilot study, and safety consideration for subjects with 
highly elevated cTn.  
The major limitation of this thesis pertains to Paper 3. As an amendment to the study 
protocol, a Reference group of study subjects (n=40) with moderately increased cTn 
was included for the CCTA study. CCTA was obtained later for these individuals, 
some almost a year after the race. The Reference group was added particularly due to 
work on the initial publication (Paper 1). We hypothesized that subjects with higher 
exercise-induced cTn levels were at higher risk of having underlying CAD. The 
Reference group was supposed to prove or disprove this hypothesis. The limited size 
of the Reference group, however, precluded us from drawing a final conclusion. 
Sample size calculation was very difficult, as no comparable studies had been 
published. Based on the pilot study, a prevalence of CAD between 25-37.5 % in the 
High-cTnI group was expected. We acknowledge that, retrospectively, this estimate 
was too high to be readily transferred to the main study. The observed difference 
between a 2.5 % and a 10 % prevalence of obstructive CAD in the Reference group 
vs the High-cTnI group was not statistically significant. The present study was 
underpowered to prove a significant difference at this level. An underpowered study 
increases the risk of type II error (false negative results). As such, we should interpret 
this non-significant difference with caution.  
In order to design a future study to find a difference between High-cTnI and 
Reference group subjects, 162 subjects would have to be included in both groups to 
have a power of 80 %. In order to identify 162 High-cTnI subjects with the same 
methodology as we used, approximately 2000 recreational athletes would have to be 
included in total. This underscores the difficulties in studying rare occurrences.     
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Lastly, multiple testing was used in all Papers, particularly in Paper 2 and 4. As this 
work was explorative, correction for multiple testing was not applied. Correcting for 
multiple testing might have been indicated, however, it also increases the risk of type 
II errors (false negative results) (217).  
10.12.1 Specific limitations of Paper 1 
The pilot study was a hypothesis generating study. The study only obtained coronary 
angiography to assess the athletes with the highest cTnI levels. Only three subjects 
with significant CAD were identified. As such, it was difficult to assess with certainty 
if maximal cTnI values were superior in predicting risk of CAD as compared to cTnI 
values at 24 hours post-race. The sampling time immediately after the race, however, 
was not found to identify subjects with underlying CAD, and as such, this sampling 
point was omitted for the main study (due to logistical concerns with two sampling 
times on one day on >1000 subjects). Also, no echocardiographic or ischemic 
assessments were obtained. Finally, a cut-off value of cTn is presented in this paper, 
based on very preliminary data. This cut-off value should be viewed with great 
caution based upon the methodology and sample size of this study.  
10.12.2 Specific limitations of Paper 2 
The major limitations of this study relate to the lack of mechanistic data such as 
echocardiographic and ischemia assessment. This was not possible due to the large 
sample size. As such, the impact of long-term cardiovascular adaptations to physical 
activity, i.e. athlete’s heart, on exercise-induced cTn increase was not assessed.  
The number of female subjects included in this study was much lower than the 
number of male subjects, reflecting the sex distribution of the North Sea Race 
participants. This should be considered when interpreting the results on sex-specific 
cTn results.  
Heart rate data was based upon self-reported sport watch measurements, and was 
only available for a subset of subjects. Data variability between different brands was 
not considered.  
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10.12.3 Specific limitations of Paper 3 
As discussed above, the Reference group was added to the study protocol after the 
race. This provided logistical and methodological challenges, and complicated the 
interpretation of the results. It also underscored the fragility of our observations: One 
study subject in the Reference group had obstructive CAD, and the FFR of his lesion 
was 0.78, obtained almost a year after the race. If this subject had not had obstructive 
CAD, the difference between the prevalence of obstructive CAD in the High-cTnI 
group and Reference group would have been 0.05 (8/78 vs 0/40, p=0.05), however, 
the fragility index would have been 1. As such, the findings from this study on the 
prevalence of obstructive CAD should be interpreted with caution.  
Due to logistic challenges with the large sample size of the original study (n=1002), 
blood sampling was limited to 24 hours before and 3 and 24 hours after the race. The 
diagnostic potential of later cTn sampling could not be assessed in the current study. 
Also, no mechanistic data such as echocardiographic and ischemia assessment was 
obtained as part of the study.  
10.12.4 Specific limitations of Paper 4 
The CRP response in this study was modest. No determination of peak O2 
consumption was obtained in order to confirm findings regarding physical fitness. We 
did not assess IL-6 or other upstream markers of inflammation in this study. The 
number of clinical events were small. Our assessment of the relationship between 
CRP and clinical endpoints should therefore be interpreted with caution. Long-term 
clinical outcomes associated with the exercise-induced CRP response is currently 
being assessed as part of the 5-year follow-up of the 2014 study subjects.  
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11. Conclusions 
Prolonged strenuous physical exercise induces a highly significant increase in 
biomarkers associated myocardial injury (cTn) and inflammation (CRP) during the 
first 24 hours following strenuous exercise. The time-dependent changes in these 
cardiac biomarkers were assessed, and predictors of the exercise-induced cTn and 
CRP increase were identified. Lastly, the relationship between cTn and CAD was 
studied, with the identification of a potentially pathological pattern of prolonged cTn 
elevation for subjects with obstructive CAD. 
11.1.1 Paper 1 
Cardiac troponin I levels increased significantly from baseline, with maximal values 
at 3 hours after the race.  
Three subjects had subclinical CAD. These were among the four with the highest 
exercise-induced cTn values after the race.  
11.1.2 Paper 2 
This large-scale study confirmed that 84-92 % of subject had cTn values above the 
99th percentile of the cTn assay 3 hours after the North Sea Race. At 24 hours after 
the race 18-30 % still had cTn values above the 99th percentile.  
Systolic blood pressure and race duration were consistent predictors of the exercise-
induced cTn response, both at 3- and 24 hours after the race. These variables were 
more important than previously reported predictors, such as body mass index, age, 
sex or training experience.  
11.1.3 Paper 3 
Cardiac troponin levels 24 hours following strenuous exercise were higher in 
asymptomatic subjects with obstructive CAD compared with subjects with no 
coronary artery obstruction, but there was no difference in cTn levels at 3 hours after 
strenuous exercise. These findings suggest a potential pathological pattern of 
prolonged elevation of cTn elevation in subjects with obstructive CAD.  
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11.1.4 Paper 4 
CRP increased significantly from baseline, with maximal values measured at 24 
hours after the race. Physical fitness was independently and inversely associated with 
the exercise-induced CRP response. This suggest that the beneficial effects of high 
degree of physical fitness might not only relate to a favourable modulation of basal 
inflammation, but also an improved biological response to physical stress. There was 
no association between the exercise-induced CRP and cTn.  
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Background: The underlying mechanisms of the exercise-induced increase in cardiac troponins (cTn) are poorly
understood. The aimof this studywas to identify independent determinants of exercise-induced cTn increase in a
large cohort of healthy recreational athletes.
Methods: A total of 1002 recreational cyclists without known cardiovascular disease or medication, participating
in a 91-kmmountain bike racewere included.Median agewas 47 years and 78%weremales. Blood sampleswere
obtained 24 h prior to, and 3 and 24 h after the race.
Results: Cardiac TnI concentrations increased markedly from baseline [1.9 (1.6–3.0) ng/L] to 3 h after the race
[52.1 (32.4–91.8) ng/L], declining at 24 h after the race [9.9 (6.0–20.0) ng/L]. Similarly, cTnT increased from
baseline [3.0 (3.0–4.2) ng/L] to 3 h after the race [35.6 (24.4–54.4) ng/L], followed by a decline at 24 h after
the race [10.0 (6.9–15.6) ng/L]. The 99th percentile was exceeded at 3 h after the race in 84% (n = 842) of sub-
jects using the cTnI assay and in 92% (n= 925) of study subjects using the cTnT assay. Shorter race duration and
higher systolic blood pressure (SBP) at baseline were highly significant (p b 0.001) independent predictors of
exercise-induced cTn increase both in bivariate and multivariable analysis. The age, gender, body mass index,
training experience and cardiovascular risk of participants were found to be less consistent predictors.
Conclusion: Systolic blood pressure and race duration were consistent predictors of the exercise-induced cTn in-
crease. These variables likely reflect important mechanisms involved in the exercise-induced cTn elevation.
Trial registration number: NCT02166216 https://clinicaltrials.gov/ct2/show/NCT02166216.
© 2019 Elsevier B.V. All rights reserved.
1. Introduction
The “Fourth definition of myocardial infarction” defines a rise and
fall pattern of cardiac troponin (cTn) above the 99th percentile as myo-
cardial injury [1]. However, following strenuous exercise there is a rise
and fall pattern in cTn in healthy subjects without evidence of irrevers-
iblemyocardial impairment [2].Most researchers therefore consider the
cTn increase in relation to exercise to be a physiological response [2–5].
The underlying mechanisms and determinants of the exercise-induced
cTn increase in healthy individuals are poorly understood. It has been
hypothesized that cTn can be released due to reversible myocyte injury
and stretch-induced apoptosis, or increased membrane permeability
with leakage of loosely bound cTn [2,6]. Exercise-induced troponin in-
crease has also been thought to be due to increased wall tension and
ventricular strain caused by volume overload, neuro-hormonal stimula-
tion and/or reversible ischaemia due to increased myocardial energy
International Journal of Cardiology xxx (xxxx) xxx
⁎ Corresponding author at: Stavanger University Hospital, PO 8400, 4068 Stavanger,
Norway.
E-mail address: oyunn.kleiven@sus.no (Ø. Kleiven).
1 This author takes responsibility for all aspects of the reliability and freedom from bias
of the data presented and their discussed interpretation.
IJCA-27473; No of Pages 8
https://doi.org/10.1016/j.ijcard.2019.02.044
0167-5273/© 2019 Elsevier B.V. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Cardiology
j ourna l homepage: www.e lsev ie r .com/ locate / i j ca rd
Please cite this article as: Ø. Kleiven, T. Omland, Ø. Skadberg, et al., Race duration and blood pressure are major predictors of exercise-induced
cardiac troponin elevation, International Journal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.02.044
demands [2,7]. Several studies have attempted to identify predictors of
the exercise-induced cTn release; however, most of these studies are
small, sampled cTn only immediately after exercise or used older cTn as-
says. Findings from these studies are conflicting, both regarding the in-
fluence of age, gender, blood pressure, body composition, training
experience and the influence of cardiovascular risk factors [2,4,8–13].
In this large-scale prospective observational study, the aim was to
identify themost important predictors associatedwith the cTn response
following strenuous exercise, using high-sensitivity cTnI and cTnT
assays.
2. Methods
2.1. Design and study population
This prospective, observational biomarker-study included recreational cyclists
≥16 years of age, residing in Norway without any previous or known CV disease. Subjects
were excluded if they reported any CV symptoms, CV treatment or disease (including cor-
onary artery disease, stroke, diabetes mellitus or hypertension requiring treatment). All
electrocardiograms (ECGs) were interpreted by experienced cardiologists, and partici-
pants were excluded if the ECG had signs of underlying CV disease: Q-waves (N3 mm in
depth or N 40 ms in duration in two or more leads except III, aVR and V1), T-inversions
(N1mm in depth in two ormore leads in V2-6, II and aVF, or I and aVL), left bundle branch
block or atrial or ventricular tachyarrhythmias. Subjects were excluded from this analysis
if they did not complete all study assessments. The study was approved by the Regional
Ethics Committee (REK 2013/550), and complies with the Declaration of Helsinki. All par-
ticipants signed informed consent forms prior to enrolment into the study. In total, 1002
participants were included in the present analysis (Supplementary Fig. 1).
2.2. Data collection
An extensive logistic systemwas developed to allow a comprehensive 30 min assess-
ment of each of the N1000 study subjects 24 h before the race, and at 3 and 24 h following
the race (Supplementary Fig. 2). The assessments included ECG, blood pressure measure-
ments, body weight and blood sampling. Detailed clinical information was obtained 5
times by digital questionnaires (Adobe FormsCentral, Adobe Systems Software Ireland
Ltd., Ireland). Start- and finishing timeswere recorded for all participants by the organizer
of the race. Subjects reported heart rate data from personal sport watches if available. Age
adjusted maximal heart rate was calculated by the formula: HRmax = 208–0.7 ∗ age [14].
2.3. Blood samples
Venous blood samples were drawn from the antecubital vein. Cardiac TnI in serum
was analyzed within 24 h at Stavanger University Hospital on an Architect i2000SR
using the high-sensitive cTnI STAT assay from Abbott Diagnostics (Abbott Diagnostics,
IL, USA). Frozen samples were transported on dry ice to Haukeland University Hospital,
Bergen, and cTnT was analyzed using a high-sensitivity cTnT assay on Cobas e601
(Roche Diagnostics, Switzerland) in serum that had not been previously thawed. The
cTnI assay has a limit of detection of 1.6 ng/L, and the overall 99th percentile of the
assay is at 26 ng/L (females: 22 ng/L, males 28 ng/L). The cTnT assay had a limit of blank
of 3 ng/L, and a 99th percentile of 14 ng/L (females: 10 ng/L, males 16 ng/L) [15]. Subjects
with cTnI values ≤ 1.6 ng/L (n= 403 at baseline, n = 0 at 3 h, n= 13 at 24 h) were given
the value 1.6. Subjects with cTnT values below 3 ng/L (n= 582 at baseline, n= 2 at 3 h, n
= 31 at 24 h) were given the value of 3 ng/L.
2.4. Statistical analysis
Normally distributed variables are reported as mean ± SD, while continuous variables
withmarkedly skewed distributions are reported asmedian and (25th percentile - 75th per-
centile). The Shapiro-Wilk test was used to test for normality. A two-tailed p-value of b0.05
was considered significant. Bivariate correlations between the cTn assays and between cTn
and variables previously suggested to be associated with exercise-induced cTn release was
assessed at baseline, 3- and 24 h after the race using Spearman's rank correlation. Multiple
linear regression analysis was used to identify predictors of the cTn response to exercise at
each sampling time-point, using a backward variable elimination procedure. The following
variables were included in the models: gender, age, resting heart rate, baseline systolic-
and diastolic blood pressure, low density lipoprotein (LDL), estimated glomerular filtration
rate (eGFRCKD-EPI), bodymass index (BMI), raceduration, Framinghamrisk score andbaseline
cTn values. Residual plotsweredeemed satisfactory after ln-transformation of the dependent
variables. Additional multiple regression analysis was performed in the cohort who reported
data from personal sport watches (n = 551), and for delta cTn values, including the same
variables as mentioned above. For categorical variables, difference in cTn was assessed by
theMann-WhitneyU test. For statistical analyses, the statistical software programs SPSS ver-
sion 24 and GraphPad Prism 7 were used.
3. Results
Participants were 46.8 (40.1–52.6) years old, 78.2% were male
(Table 1). Race duration was 3.7 (3.4–4.2) hours. None of the subjects
included in this study reported CV symptoms during or following the
race.
3.1. Cardiac troponin kinetics
The distributions of cTn values at baseline and at 3- and 24 h after the
race are shown in Fig. 1. At baseline, a total of 40.2% (cTnI) and 58.1%
(cTnT) had cTn values below the limit of detection (Table 1, Fig. 1). Car-
diac TnI concentrations increased markedly from baseline [1.9 (1.6–3.0)
ng/L] to 3 h after the race [52.1 (32.4–91.8) ng/L], declining at 24 h after
the race [9.9 (6.0–20.0) ng/L]. Similarly, cTnT increased from baseline
[3.0 (3.0–4.2) ng/L] to 3 h after the race [35.6 (24.4–54.4) ng/L], followed
by a decline at 24 h after the race [10.0 (6.9–15.6) ng/L]. Due to the
skewed cTn distribution, mean cTn values were higher at all time-
points, and are outlined in Supplementary Table 1. Cardiac TnI values
exceeded the 99th percentile (26 ng/L) in 84% of study subjects at 3 h
and 18% at 24 h following the race. Cardiac TnT values exceeded the
99th percentile (14 ng/L) in 92% of study subjects at 3 h, and 30% at
24 h following the race. Delta cTnI between 3 h post-race and baseline
(ΔcTnI 3-0 h) was 49.9 (29.4–87.0) ng/L. Delta cTnT (ΔcTnT 3-0 h)
was 31.7 (20.6–50.1) ng/L. Cardiac troponin values at 24 h after
the race were also higher than baseline levels in virtually all subjects;
Table 1
Baseline characteristics of subjects included in the study.
Total cohort (n = 1002)
Age, years 46.8 (40.1–52.6)
Males, % 782 (78.2%)
BMI, kg/m2 25.3 (23.7–27.3)
Body weight, kg 82.1 (74.6–89.4)
Systolic blood pressure, mmHg 136 (126–148)
Diastolic blood pressure, mmHg 79 (73–86)
Waist circumference, cm 86.0 (80–92)
Family history of sudden death/early myocardial
infarction, n (%)
187 (18.7%)
History of hypertension, n (%) 23 (2.3%)
Current smokers, n (%) 13 (1.3%)
Framingham risk score, %a 1 (0–5)
Physical fitness
Resting heart rate, beats/min 59 (53–67)
MET hours per weekb 51.3 (31.8–80.0)
Number of races past 5 y, n (%) 7 (3–15)
Self-reported maximal heart rate, beats/min 185 (178–193)
Race performance
Race duration, hours 3.7 (3.4–4.2)
Maximal heart rate during the race, beats/min 178.0 (170–186)
Maximal heart rate of estimated maximal heart rate, % 100.4 (96.8–104.4)
Mean heart rate during the race, beats/min 157.0 (148.0–165.0)
Mean heart rate of estimated maximal heart rate, % 88.6 (84.5–92.5)
Biomarkers at baseline
cTnI, ng/Lc 1.9 (1.6–3.0)
cTnT, ng/Ld 3.0 (3.0–4.2)
BNP, pg/mL 13.4 (10.0–21.2)
CRP, mg/L 0.7 (0.4–1.3)
Creatinine, umol/L 83.8, SD: 11.7
eGFR, mL/min/1.73m2 91.3, SD: 12.7
Total Cholesterol, mmol/L 5.1 (4.6–5.8)
LDL, mmol/L 3.2 (2.6–3.7)
HDL, mmol/L 1.5 (1.3–1.7)
Hemoglobin, g/dL 14.5, SD: 1.0
a Framingham risk score: 10-year risk of death or myocardial infarction.
b MET = Metabolic equivalents of task (3.5 mL O2/kg/min). Estimated by IPAQ-SF.
c 40.2% had cTnI values ≤ 1.6 ng/L (limit of detection).
d 58.1% had cTnT values ≤ 3.0 ng/L (limit of blank).
2 Ø. Kleiven et al. / International Journal of Cardiology xxx (xxxx) xxx
Please cite this article as: Ø. Kleiven, T. Omland, Ø. Skadberg, et al., Race duration and blood pressure are major predictors of exercise-induced
cardiac troponin elevation, International Journal of Cardiology, https://doi.org/10.1016/j.ijcard.2019.02.044
ΔcTnI 24 h–0 h: 7.4 (3.7–16.5) ng/L,ΔcTnT 24 h–0 h: 6.3 (3.3–11.1) ng/L,
all p b 0.001.
The correlation between cTnI and cTnT at baseline was moderate
(rho = 0.60, p b 0.001), likely due to a high number of subjects with
cTn values below the limit of detection. At 3- and 24 h after the race,
the correlation was closer (3 h: rho = 0.87, p b 0.001, 24 h: rho =
0.76, p b 0.001).
3.2. Factors associated with cTn levels at baseline and following exercise
Baseline systolic blood pressure and race duration were consistently
related to both cTnI and cTnT at all time-points following the race
both in bivariate and multivariable models (Table 2, Fig. 2). At baseline
age, systolic- and diastolic blood pressure, BMI, body weight, waist cir-
cumference, Framingham risk score and LDL-levels were positively
Fig. 1. Distribution of cTn at baseline, and at 3- and 24 h after the race, red indicates female subjects; blue male subjects. Dotted lines represent the sex-specific 99th percentile. (For
interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Table 2
Bivariate correlations (Spearman's Rank Correlation) and multiple linear regression models for cTn at different time-points (n = 1002). B signifies the regression coefficient. Variables
included in the multiple regression analysis: gender, age, resting heart rate, baseline systolic- and diastolic blood pressure, low density lipoprotein (LDL), estimated glomerular filtration
rate (eGFR), body mass index (BMI), race duration, Framingham risk score and baseline cTn values. A backward variable elimination procedure was used.
cTnI baseline cTnT at baseline
Bivariate correlations Multiple regression
(R2 = 0.06)
Bivariate correlations Multiple regression
(R2 = 0.16)
Rho p-value B p-value Rho p-value B p-value
Age, years 0.17 b0.001 Ns 0.30 b0.001 Ns
Gender, males 0.22 b0.001 Ns 0.26 b0.001 0.110 b0.001
Resting heart rate, bpm −0.18 b0.001 −0.010 b0.001 −0.14 b0.001 −0.004 0.001
Systolic BP, mmHg 0.21 b0.001 0.005 0.002 0.19 b0.001 0.002 0.004
Race duration, hours −0.16 b0.001 −0.088 0.008 −0.10 0.003 Ns
eGFR, mL/min/1.73m2 −0.10 0.001 Ns −0.23 b0.001 −0.004 b0.001
LDL, mmol/L 0.09 0.005 Ns 0.07 0.03 −0.023 0.084
Framingham risk score, % 0.23 b0.001 0.018 0.004 0.37 b0.001 0.021 b0.001
BMI, kg/m2 0.10 0.002 0.016 0.035 0.09 0.005 Ns
Body weight, kg 0.18 b0.001 0.17 b0.001
Waist circumference, cm 0.14 b0.001 0.17 b0.001
Diastolic BP, mmHg 0.16 b0.001 0.15 b0.001
MET hours per week 0.05 0.158 0.06 0.059
HDL, mmol/L −0.02 0.598 −0.04 0.271
Endurance training, years 0.12 0.001 0.10 0.005
Maximal heart rate race, bpm −0.13 0.004 −0.22 b0.001
% maximal HR of estimated max −0.08 0.069 −0.08 0.052
Mean HR during race, bpm −0.12 0.006 −0.21 b0.001
% mean HR of estimated max −0.07 0.116 −0.07 0.083
cTnI 3-h post-race cTnT 3-h post-race
Bivariate correlations Multiple regression
(R2 = 0.15)
Bivariate correlations Multiple regression
(R2 = 0.16)
Rho p-value B p-value Rho p-value B p-value
Age, years −0.05 0.094 −0.014 0.001 0.03 0.351 −0.004 0.087
Gender, males 0.05 0.152 −0.269 0.002 0.16 b0.001 Ns
Resting heart rate, bpm −0.03 0.382 Ns −0.07 0.036 Ns
Systolic BP, mmHg 0.14 b0.001 0.006 b0.001 0.14 b0.001 0.004 b0.001
Race duration, hours −0.15 b0.001 −0.228 b0.001 −0.25 b0.001 −0.216 b0.001
eGFR, mL/min/1.73m2 0.03 0.403 Ns −0.03 0.402 Ns
LDL, mmol/L −0.02 0.498 Ns 0.09 0.004 Ns
Framingham risk score, % −0.01 0.73 0.020 0.090 0.09 0.003 Ns
BMI, kg/m2 0.04 0.225 0.019 0.045 0.02 0.458 Ns
Baseline cTn, ng/L 0.31 b0.001 0.346 b0.001 0.29 b0.001 0.442 b0.001
Body weight, kg 0.08 0.008 0.10 0.002
Waist circumference, cm 0.03 0.309 0.05 0.131
Diastolic BP, mmHg 0.06 0.053 0.05 0.137
MET hours per week −0.03 0.438 0.03 0.431
HDL, mmol/L 0.00 0.998 −0.02 0.550
Endurance training, years −0.07 0.050 −0.04 0.206
Maximal heart rate race, bpm 0.10 0.026 0.00 0.917
% maximal HR of estimated max 0.02 0.606 −0.02 0.62
Mean HR during race, bpm 0.14 0.001 0.11 0.011
% mean HR of estimated max 0.07 0.092 0.90 0.048
cTnI 24-h post-race cTnT 24-h post-race
Bivariate correlations Multiple regression
(R2 = 0.36)
Bivariate correlations Multiple regression
(R2 = 0.28)
Rho p-value B p-value Rho p-value B p-value
Age, years 0.15 b0.001 0.008 0.008 0.16 b0.001 Ns
Gender, males 0.13 b0.001 Ns 0.30 b0.001 0.092 0.096
Resting heart rate, bpm −0.08 0.013 Ns −0.09 0.004 Ns
Systolic BP, mmHg 0.22 b0.001 0.007 b0.001 0.23 b0.001 0.005 b0.001
Race duration, hours −0.16 b0.001 −0.142 b0.001 −0.28 b0.001 −0.199 b0.001
eGFR, mL/min/1.73m2 −0.08 0.015 Ns −0.09 0.006 Ns
LDL, mmol/L 0.07 0.026 Ns 0.09 0.004 0.040 0.067
Framingham risk score, % 0.20 b0.001 Ns 0.37 b0.001 Ns
BMI, kg/m2 0.09 0.030 0.024 0.010 0.14 b0.001 0.024 b0.001
Baseline cTn, ng/L 0.51 b0.001 0.765 b0.001 0.44 b0.001 0.637 b0.001
Body weight, kg 0.14 b0.001 0.22 b0.001
Waist circumference, cm 0.11 0.001 0.19 b0.001
Diastolic BP, mmHg 0.14 b0.001 0.14 b0.001
MET hours per week 0.02 0.533 0.04 0.182
HDL, mmol/L 0.00 0.973 −0.09 0.007
Endurance training, years 0.03 0.415 0.02 0.584
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correlated with cTn, while resting heart rate, race duration, mean heart
rate during the race, and eGFR were negatively correlated (Table 2). A
similar pattern was detected for correlations with cTn at 24 h after the
race.
Age was inversely associated with the cTnI response at 3 h after the
race, but positively correlated at baseline and 24 h after the race.
A total of 219 females (22%) were included into the analysis. Female
participants were younger than the male cohort (45.7 (38.8–51.1) ver-
sus 47.2 (40.3–53.2) years, p = 0.022). They also had lower systolic
blood pressure (127 (120–140) vs 138 (129–150) mmHg, p b 0.001),
lower BMI (23.8 (22.2–25.8) vs 25.6 (24.3–27.6) kg/m2, p b 0.001),
and they finished the race 0.8 h slower than their male counterparts
(4.5 (4.0–5.0) vs 3.7 (3.3–4.0) hours, p b 0.001).
Both cTnI and cTnT were significantly higher in male as compared
with female cyclists both at baseline and at 24 h after the race. At 3 h
after the race, male participants had significantly higher cTnT but not
cTnI values. The number of participants who exceeded the sex-specific
99th percentile at all time-points was similar for both genders (Supple-
mentary Table 2). Female gender remained a significant predictor for
higher cTnI 3 h after the race (B = −0.27, p = 0.002), but not for
cTnT. At 24 h after the race, gender was a borderline significant predic-
tor of the cTnT (B = 0.09, p = 0.096), but not the cTnI response.
Table 2 (continued)
cTnI 24-h post-race cTnT 24-h post-race
Bivariate correlations Multiple regression
(R2 = 0.36)
Bivariate correlations Multiple regression
(R2 = 0.28)
Rho p-value B p-value Rho p-value B p-value
Maximal heart rate race, bpm −0.03 0.444 −0.05 0.241
% maximal HR of estimated max −0.02 0.640 −0.02 0.638
Mean HR during race, bpm −0.01 0.850 0.07 0.088
% mean HR of estimated max 0.02 0.621 0.11 0.009
Fig. 2. Median cardiac troponin values plotted against tertiles of race duration and baseline systolic blood pressure a) cTnI 3 h post-race, b) cTnT 3 h post-race, c) cTnI 24 h post-race,
d) cTnT 24 h post-race, n = 1002.
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Baseline cTn values were closely associated with the post-exercise
cTn values in multiple regression analysis. A secondary analysis on the
delta increase in cTn from baseline to 3 h after the race and from base-
line to 24 h after the race was performed, and systolic blood pressure
and race duration remained independent predictors of the cTn increase
in these models (Supplementary Table 3).
Only 55% (n = 551) reported heart rate data from personal sport
watches, and heart rate variables were therefore not included in the
multiple regression models. An analysis that included the variable
“mean heart rate during the race” was performed in the cohort with
heart rate data. In this model, the associations between mean heart
rate during the race and cTnI at 3-h post-race (B = 0.004, p = 0.077)
and with cTnT 24 h post-race (B = 0.003, p = 0.028) were borderline
significant. Mean heart rate did not remain a significant predictor for
cTnT 3 h post-race or cTnI 24 h after the race.
Levels of low-density lipoprotein cholesterol (LDL-C) at baseline
were not associated with the cTn response at either 3 or 24 h after the
race, nor were the Framingham risk score (Table 2). A total of 31 sub-
jects reported a first degree relative with premature cardiovascular dis-
ease (b50 years of age). These subjects did not have a different cTn
response than the rest of the cohort. Subjects above the age of
35 years that fulfilled the High-Risk criteria proposed for recreational
athletes (n = 238, 23.8%) were also assessed separately. Increased
BMI was the most common cause for High-Risk classification (n =
183, 76.9%, Supplementary Fig. 3). High-Risk individuals had similar
levels of cTn at 3 h after the race and higher cTn levels at 24 h post-
race (cTnI: 12.3 (6.8–25.6) vs 9.6 (5.9–18.6) ng/L, p = 0.001, cTnT:
11.5 (7.8–18.5) vs 9.9 (6.7–15.0) ng/L, p b 0.001, Supplementary Fig. 4).
Some of the included subjects reported several co-morbidities and
intake of different supplements. (Supplementary Table 4–5): 31.8% of
subjects (n = 319) reported to use supplements regularly, while
27.7% of subjects (n=278) never used supplements. Therewere nodif-
ference in cTn kinetics between subjects who used supplements and
those who did not.
4. Discussion
This is the largest study ever performed to determine the predictors
of the exercise-induced cTn response. Troponin levels increased in all
subjects, with N84% of subjects exceeding the 99th percentile of the
cTn assays at 3 h following exercise. At 24 h 18–30% of subjects still
had cTn levels above the 99th percentile. Systolic blood pressure and
race duration were consistent predictors of cTnT and cTnI levels at all
time-points following exercise. Other previously suggested variables
were less consistently associated with the cTn increase. The strength
of this study is the large number of study subjects, allowing the inclu-
sion of all previously suggested predictors of the exercise-induced cTn
increase, the use of two different high-sensitivity cTn assays, andmulti-
ple cTn sample time-points. However, despite the large sample size
allowing inclusion of all previously suggested predictors, the post-race
multiple regression models only explained a variance of 15–36% of
cTn levels following exercise. Considering this, the present study
shows that additional unidentified factors are involved in and needed
to improve the prediction and understanding of the exercise-induced
cTn response.
4.1. Exercise-induced cTn elevation
There is limited understanding of the underlyingmechanisms of the
physiological cTn increase following exercise. A leading current hypoth-
esis is that stress can cause reversible cardiac injury leading to cell
wounds, cytoplasmatic blebbing, and the release of intracellularmacro-
molecules, as well as activation of apoptosis [6]. Irreversible injury with
necrosis of cardiomyocytes and degradation of cTn by lysosomal en-
zymes are however, difficult to distinguish from the reversible causes
based on systemic cTn levels alone, and current imaging modalities
lack the sensitivity to identify non-focal necrosis [6]. Several mecha-
nisms causing exercise-induced cTn release have been proposed. It has
been hypothesized that cTn can be released due to exercise-induced in-
crease in wall tension and ventricular strain, neuro-hormonal stimula-
tion and/or reversible ischemia due to increased myocardial energy
demand [2,6,7].
The present study demonstrates an increase in both cTnI and cTnT in
all subjects following strenuous exercise. This finding supports that
exercise-induced cTn increase in healthy subjects is a physiological
response.
4.2. Exercise intensity and duration
In this study, there was a consistent inverse relation between cTn
levels and race duration in both bivariate and multiple regression
models (Table 2, Supplementary Table 3). Previous studies assessing
the relationship between the cTn response and race duration have
been conflicting: Some studies found a direct correlation [3,16,17],
whereas others found an inverse correlation [4,13] or no correlation
[11,12,18]. Although race duration is a readily available parameter, the
interpretation of this variable is complex. Race duration is related to
physical fitness [19]. However, it also reflects sport specific technical
skills, exercise intensity and the duration of high-intensity work.
Shorter race duration requires higher velocity, which necessitates
higher exercise intensity. Exercise intensity and the duration of high-
intensity work are important predictors of the exercise-induced cTn re-
sponse. The intensity of the work required to induce a significant in-
crease in the exercise-induced cTn response has recently been
addressed by Stewart et al. [20]. In their study, a marked increase in
exercise-induced cTn was found following a 90 min ergometer cycling
test, when exercise was performed with an exercise intensity above
the gas exchange threshold. The present population-based study and
the mechanistic study by Stewart et al. underscore the importance of
the intensity-duration domain as an important determinant for cTn
elevation.
4.3. Systolic blood pressure
A major finding of the present study was the consistent relationship
between systolic blood pressure measured prior to the race and cTn ele-
vations both at 3- and 24 h after the race. Systolic blood pressure has not
been included in the multiple regression analyses in previous studies
[10,12,13]. However, some smaller studies have reported bivariate corre-
lations between blood pressure and exercise-induced cTn increase
[21,22]. Our finding is intriguing, and in line with the recent mechanistic
study byWeil and al., that observed a transient increase in cTnI following
phenylepinephrine infusion in a pig model [7]. The phenylepinephrine
infusion caused increased systolic blood pressure and increased left ven-
tricular end diastolic pressure in the absence of ischaemia. Our findings
and the mechanistic work by Weil et al., suggest that the exercise-
induced cTn increase in healthy subjects is related to increase in cardiac
work, both in response to mechanical work and potentially due to in-
creased neuro-hormonal activity induced by strenuous physical exercise
and the competitive situation.
4.4. Body composition
The present study found inconsistent correlations between cTn and
BMI, body weight and waist circumference at 3- and 24 h after the
race. There are conflicting reports on the relationship between cTn
and BMI underscoring the complexity of this association; Eijsvogels
et al. found no significant association with exercise-induced cTn in-
crease [9], while a meta-regression analysis found increased body
weight to be a major predictor [4]. BMI was originally established to
measure tissue mass and obesity [23]. However, BMI does not reflect
body tissue composition. In a healthy athletic population, increased
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weight may reflect a higher muscular proportion compared with a
larger proportion of adipose tissue in a sedentary population [24].
Increased BMI may increase work load during physical exercise and
thereby influence the levels of work-load dependent biomarkers.
The interpretation of the relationship between BMI and exercise-
induced cTn response, however requires careful interpretations,
particularly in relation to a potential collinearity between body
weight and performance [4]. Waist circumference was also used to
assess the potential impact of body composition on the exercise-
induced cTn response. Waist circumference did not provide
additional benefit compared with BMI in the prediction of the
exercise-induced cTn increase.
4.5. Age and gender
Following exercise there was no clear relationship between age and
cTn levels. These inconsistent results are in line with previous studies
that present conflicting data on the relationship between age and the
exercise-induced cTn release: some studies indicate increased cTn
levels in younger subjects [11–13], some studies indicate increased
cTn levels in older athletes [10,25], whereas others report no correla-
tions [26,27]. Our study suggests that age is not a major independent
predictor of exercise-induced cTn increase. However, since only 61 sub-
jects (6.1%) were above 60 years of age, future studies will need to con-
firm our findings in subjects above middle-age.
Women have lower cTn levels at baseline than men, and gender-
specific cTn cut-off values have been proposed. Gender differences
have also been found to influence the exercise-induced cTn release in
some studies [11,28]. In our cohort, the number of subjects who
exceeded the gender-specific cTn cut-off at all time-points was similar
for male and female participants, and the cTn distributions were fairly
equal (Fig. 1, Supplementary Table 2). In multiple regression analysis,
however, females were found to have a higher cTnI increase as com-
pared to men at 3 h after the race when adjusted for other variables.
This finding was not identified for the cTnT assay.
4.6. Training experience
Training experience has been found to be inversely associated with
post-exercise cTn in several studies [8,10,11]. The present study used
several measures to estimate training condition. Training and competi-
tive experiencewasmeasured as number of years of endurance training
and number of endurance exercise competitions during the past five
years. No significant association was found between this measure and
cTn levels. The International Physical Activity Questionnaire (IPAQ)
was used to assess the amount of exercise prior to the race. No relation
was found between this measure and exercise-induced cTn. Our find-
ings argue against a major relationship between training experience
and cTn response.
4.7. Other cardiovascular risk factors
CV risk factors like cholesterol levels, family history of premature CV
disease and Framingham risk were not found to significantly affect the
exercise-induced cTn increase.
The ESC sports cardiology group has proposed specific criteria for
identifying recreational athletes above 35 years of age at increased
risk of sport-related cardiac events [29]. Using the proposed criteria, a
total of 238 (23.8%) of our participants were classified as High-Risk
individuals due to the presence of at least one CV risk factor. A
higher cTn level 24 h after the race was identified in this High-risk
group (p b 0.01, Supplementary Fig. 4). The clinical implications of
this finding remain to be determined.
4.8. Limitations
There are some limitations that apply to the current study: First, with
this large sample size, it was impossible to include mechanistic data be-
yond biomarkers and biometrics acquired during the study. The major
limitations therefore relate to the lack of mechanistic data such as echo-
cardiographic and ischemia assessment. Second, the present cohort was
primarily middle-aged male subjects, and the findings may therefore
not apply in a very young (b20 years of age) or an above middle aged
(N60 year of age) population. Third, undiagnosed coronary artery disease
maybeprevalent in this population. The impact of coronary artery disease
on exercise-induced cTn increase remains to be elucidated. Fourth, the
clinical implications of the current findings need to be determined. The
clinical implications will be assessed by pre-specified follow-up studies
at 5-, 10- and 20 years following inclusion. Fifth, the present cohort
consisted of recreational athletes with a higher fitness level compared
with the general population. The impact of cardiovascular adaptations
to long-term physical activity, i.e. athlete's heart, on exercise-induced
cTn increase was not assessed in the present study. Sixth, the number of
female subjects included in this study is much lower than the number
of male subjects. This should be considered when interpreting the results
on sex-specific cTn results. Seventh, heart rate data was based upon self-
reported sport watchmeasurements from study subjects. Data variability
between different brands was not considered.
5. Conclusion
In this large-scale prospective observational study, systolic blood
pressure and race duration were consistent predictors of the exercise-
induced cTn increase. These variables weremore important than previ-
ously reported predictors of the exercise-induced cTn increase, such as
body mass index, age, gender or training experience.
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C- reactive protein (CRP) increases after strenuous exercise. It has been a concern that 
prolonged strenuous exercise may be harmful and induce a deleterious inflammatory 
response. The purpose of this study was to (a) assess and quantify the magnitude of 
CRP response following an endurance cycling competition in healthy middle- aged rec-
reational cyclists. (b) Identify important determinants of this response. (c) Identify the 
relationship between CRP, myocardial damage (cardiac Troponin I (cTnI)), and myo-
cardial strain (B- type natriuretic peptide [BNP]). (d) Identify the relationship between 
CRP and clinical events, defined as utilization of healthcare services or self- reported 
unusual discomfort. Race time was used as a measure of physical fitness. A total of 97 
individuals (43±10 years of age, 74 [76%] males) were assessed prior to and 0, 3, and 
24 hours following the 91- km mountain bike race “Nordsjørittet” (Sandnes, Norway, 
June 2013). There was a highly significant increase in CRP from baseline to 24 hours 
(0.9 (0.5- 1.8) mg/L vs. 11.6 (6.0- 17.5) mg/L (median[IQR]), P<.001), with no correla-
tion of CRP to cTnI and BNP at any time- point. CRP was strongly correlated to race 
time at baseline (r=.38, P<.001) and at 24 hours following the race (r=.43, P<.001), 
In multivariate models, race time was an independent predictor of CRP both at baseline 
and at 24 hours (P<.01). There was no relationship between CRP levels and clinical 
events. In conclusion, high physical fitness was associated with reduction in both basal- 
and exercise- induced CRP. No adverse relationship was found between high intensity 
physical exercise, CRP levels, and outcomes.
K E Y W O R D S
bicycling, cardiovascular risk factors, C-reactive protein, endurance exercise, healthy individuals, 
recreational sport
1 |  INTRODUCTION
Resting levels of the inflammatory marker C- reactive protein 
(CRP) are strongly associated with increased risk of cardio-
vascular (CV) events.1-4 An inverse relationship between 
physical fitness and basal CRP has been demonstrated.5,6 
Increased physical activity is associated with reduced risk of 
CV events.7-10 Physical activity is therefore recommended for 
the prevention of CV disease.11 Participation in recreational 
sports competitions represents an important motivation 
2 |   ﻿KLEILEN Let Kl
to many that perform physical training on a regular basis. 
However, there is a concern that the strenuous physical ac-
tivity during these competitive events may be harmful.12-15 
Previous studies have suggested a small but significant in-
creased risk of sudden death related to strenuous physical ex-
ercise.16-19 Following physical exercise, there is an increase 
in CRP levels.7,20-22 This increase in CRP has not been asso-
ciated with adverse events in prior studies that have included 
highly selected populations of well- trained athletes partici-
pating in ultra- endurance events and marathons.20,22,23 There 
are limited data on the relationship between prolonged high 
intensity physical exercise and the inflammatory response in 
unselected populations of recreational sport participants with 
a larger range of fitness. Medium length recreational sport 
bicycle races are less physically demanding than marathons. 
It may therefore be anticipated that these bike races attract 
a population of participants with a greater range of physical 
fitness at greater risk of CV disease.
The aim of this study was to (a) assess and quantify the 
magnitude of the exercise- induced CRP response following 
an endurance cycling competition in presumably healthy 
middle- aged recreational cyclists. (b) Identify important de-
terminants of the CRP response following exercise, and in 
particular to assess the influence of physical fitness on base-
line and post- exercise CRP levels. (c) Identify the relation-
ship between CRP levels and markers of myocardial damage 
(cardiac Troponin I [cTnI] and myocardial strain (B- type na-
triuretic peptide [BNP]). (d) Identify the relationship between 
CRP levels and clinical events for the first week following 
the race. Clinical events were defined as either utilization of 
healthcare services or self- reported unusual discomfort.
2 |  METHODS
This is a prospective observational study. Study participants 
were recruited among cyclists participating in the 2013 edi-
tion of the 91- km North Sea Race (“Nordsjørittet”).21 This 
is an annual mountain bike race attracting approximately 
12 500 participants with a great range of different fitness 
levels. The regional ethics committee (2013/550/REK vest) 
approved the study. All participants gave written informed 
consent prior to enrollment into the study.
2.1 | Study population
Participants in the North Sea Race 2013 without medical 
treatment and any known disease were invited to partici-
pate in the study. All study participants were recruited by an 
electronic form, distributed on the Internet through the of-
ficial website of the North Sea Race (www.nordsjorittet.no). 
Eligible participants that signed the informed consent and 
completed the four blood samples were included in the study.
2.2 | Acquisition of blood samples, patient 
demographics, and biometric measurements
Blood samples, resting ECG, blood pressure, and bodyweight 
were acquired approximately 24 hours prior to the race (base-
line) and 0, 3, and 24 hours following the race. Detailed in-
formation regarding demographics, medical history, degree 
of fitness, physical condition, and nutrition was acquired by 
six electronic questionnaires (Adobe FormsCentral, Adobe 
Systems Software Ireland Ltd., Ireland). All participants were 
advised to use a heart rate monitor to determine the individual 
heart rate during the competition. Heart rate was reported both 
as median and max heart rate. Heart rate was also transformed 
into percent of max age- adjusted heart rage: HRmax=208- 0.7* 
age (years).24 Race time was recorded by an electronic time- 
keeping system supplied by the organizer of the race.
Venous blood samples were acquired at all the four time- 
points. For hematology and HbA1c, 3- mL K2 EDTA tubes 
were used. For CRP, creatine kinase (CK), creatinine, and 
estimated glomerular filtration rate (eGFR) serum analyses 
were used. For CRP, a high sensitivity assay was used. Serum 
separation tubes with K2 ethylenediaminetetraacetic acid 
(EDTA) were used for analyses of BNP. The troponins were 
analyzed using a high- sensitive cardiac troponin I STAT assay 
from Abbott Diagnostics with a lower limit of detection of 
1.6 ng/L. The tubes were stored in a refrigerator until analysis. 
Tubes without any additives were placed in room tempera-
ture and centrifuged after coagulation at 2000 g for 10 min-
utes. Following centrifugation, all blood samples were stored 
at +4°C and transported to Stavanger University Hospital for 
analysis within 24 hours. The biomarkers were analyzed using 
Architect c16000TM and Abbott Architect i2000TM (Abbott 
Diagnostics, IL, USA) (clinical chemistry) and Variant Turbo 
II (Bio- Rad Laboratories, Hercules, CA, USA) (HbA1c).
2.3 | Determination of physical fitness
Physical fitness has been defined as “The ability to carry out 
daily tasks with vigor and alertness, without undue fatigue 
and with ample energy to enjoy (leisure) pursuits and to 
meet unforeseen emergencies”.25 Physical fitness is opera-
tionalized as “(a set of) measurable health and skill- related 
attributes” that include cardiorespiratory fitness, muscular 
strength and endurance, body composition and flexibility, 
balance, agility, reaction time and power.11 Race time in a 
bike race reflects all the core attributes of physical fitness: 
cardiorespiratory fitness, muscular strength and endurance, 
body composition and flexibility, balance, agility, reaction 
time, and power. Race time was therefore chosen as the pri-
mary measure for physical fitness.
During a competitive event, accidents or other obstacles that 
preclude the interpretation of race time as marker of physical 
fitness may occur. We therefore also included a self- evaluation 
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of physical fitness that the participants had to hand in prior to 
the race. In this self- evaluation of physical fitness, the study par-
ticipants had to grade their own fitness level (5 levels) compared 
with other contestants at the same age. In addition, we also at-
tempted to assess prior history of physical fitness by the number 
of participations in recreational sport competitions during the 
past 5 years, and their training level by the number of training 
hours per week during the past 3 months prior to the race.
2.4 | Clinical outcomes
All study participants reported clinical events 1 week after 
the race. Clinical endpoints were defined as any unscheduled 
healthcare contact, sick leave, or any kind of unusual discom-
fort following the race. Discomfort was defined as an affirm-
ative response to the following question 1 week following the 
race: “Have you been experiencing more than expected pain 
or exhaustion following the race?”
2.5 | Statistics
In accordance with a previous study in marathon runners, the 
aim was to include 100 study subjects.20 With 100 patients, bi-
variate correlations of size |r|=.27 have a power of 80%, and 
for |r|=.32, there is a power of 90%, both at a two- sided 0.05 
significance level. Mean and standard deviation (SD) were used 
to report continuous variables, and median and interquartile 
range (IQR) were used to report markedly skewed distributions. 
Nonparametric tests were used for the assessment of correlations 
(Spearman) and longitudinal changes (Mann- Whitney U test) 
and comparisons between and within groups (Kruskal- Wallis 
and Wilcoxon). Regression analyses are justified based on as-
ymptotic normality due to the fairly large size of the data set. 
Backward stepwise variable selection was used in the regression 
analyses. The covariates that were included in the model were 
variables known to influence CRP: baseline CV risk factors, 
physical fitness, and muscle damage (only following exercise 
for CRP). A two- tailed P- value of <.05 was considered signifi-
cant. For all statistical analyses, the statistical package SPSS 
version 23 (IBM, NY, USA) and R (R Foundation for Statistical 
Computing, Vienna, Austria) were used.
3 |  RESULTS
Ninety- seven healthy cyclists were included in the study (Table 1). 
Study participants were 42.8±9.6 years of age, 74 (76%) were 
males, 43 (44%) had never smoked. There were no diabetics. 
Mean race time was 4:22±0:52 (hour:minute) with a mean heart 
rate of 156±17 bpm which is 86±14% of estimated age- adjusted 
max heart rate. There was a large range in training hours per week 
among study subjects; one study participant logged 28 training 
hours/week, and six logged <3 hours/week. Likewise, there was 
a large range in competitive activity during last 5 years prior to 
the study: 10 subjects had no competitive experience, whereas 13 
subjects had participated in more than 30 competitions.
3.1 | CRP levels before and after exercise
There was a highly significant increase in CRP from base-
line to 24 hours (0.9 [0.5- 1.8] mg/L vs. 11.6 [6.0- 17.5] mg/L, 
P<.001) (median [IQR]). CRP values at baseline and at 
24 hours following the race were not correlated to gender, 
age, or injury during the race (Table 2).
3.2 | Physical fitness and CRP levels
There was a highly significant (P<.001) increase in CRP fol-
lowing exercise in all four measures of physical fitness, with the 
highest CRP levels in the least fit study participants (Figure 1).
T A B L E  1  Baseline characteristics and competition performance 
of the study participants, North Sea Race, Sandnes, Norway, June 2013 
(n=97), mean±SD or median (IQR) for markedly skewed 
distributions, or number, %
Gender (male, %) 74 (76.3)
Age (y) 42.8±9.6
Weight (kg) Body mass index (kg/m2) 83.4±14.0 
25.3 (23.4- 28)
Blood pressure (mm Hg)
 Systolic 138 (129- 152)
 Diastolic 77 (71- 85)






 HbA1c (%) 5.3±0.27
 Total cholesterol (mmol/L) 4.9 (4.4- 5.5)
 HDL (mmol/L) 1.3 (1.1- 1.6)
 LDL (mmol/L) 3.2±0.84
 eGFR (ml/min/1,73 m2) 94±13.9
 ECG: left ventricular hypertrophy (n, %) 29 (30)
Training history
 No. of endurance competitions past 5 y 7 (2- 16)
 Hours of training per week past 3 mo 7.0 (5- 10)
North Sea Race 2013
 Finishing time (h:min) 4.1 (3.6- 4.7)
 Max heart rate (bpm) 180 (174- 188)
 Max heart rate of expected max heart rate (%) 96.7 (95- 100)
 Mean heart rate (bpm) 158 (148- 168)
 Mean heart rate of expected max (%) 86 (82- 88)
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Study participants with the fastest race times (Q1) were 
taller and consisted only of men; they also reported higher 
self- assessed fitness level (Table 3). There were no differ-
ences in age and BMI between riders in the different race 
time quartiles (Table 3).
Figure 1 illustrates the differences in CRP levels between 
different measures of physical fitness and training. When 
participants were divided according to race time quartile 
(Figure 1A), there was a significant difference between 
CRP levels at baseline (P=.004), immediately after the race 
(P<.001), 3 hours after the race (P<.001), and 24 hour after 
the race (P<.001). When patients were divided into quar-
tiles based on number of previous competitions (Figure 1C), 
there was no significant difference in CRP levels at baseline 
(P=.152) but highly significant differences following com-
petition: immediately after the race (P<.001), 3 hours after 
the race (P=.009), and 24 hour after the race (P<.001). 
When patients were asked to assess personal degree of fit-
ness (Figure 1B), the majority of participants answered 
“good” or “moderate” (n=67). There was a significant dif-
ference between groups at baseline (P=.01), immediately 
after the race (P=.001), 3 hours after the race (P<.001), 
and 24 hour after the race (P<.001). When patients were di-
vided into quartiles of training hours per week (Figure 1D), 
there was no significant difference until 24 hours after the 
competition: baseline (P=.20), immediately after the race 
(P=.061), 3 hours after the race (P=.04), and 24 hour after 
the race (P<.016).
CRP (Baseline) 
median (IQR) P- value
CRP (24 h) median 
(IQR) P- value
Sex
 Women (24%) 0.8 (0.5- 2.0) 11.0 (4.7- 21.2)
 Men (76%) 1.0 (0.5- 1.8) .71 11.7 (6.2- 17.4) .96
Age (y of age)
 >42 (55%) 1.0 (0.5- 2.0) 8.6 (4.2- 17.5)
 <42 (45%) 0.8 (0.5- 1.9) .75 11.8 (8.0- 17.7) .10
Smoking status
 Never (51%) 0.8 (0.5- 1.5) 9.8 (5.8- 15.7)
 Previous (40%) 1.0 (0.5- 2.1) 12.9 (5.1- 20.6)
 Current smoker (4%) 1.3 (0.8- 6.8) .23 16.2 (10.3- 35.5) .21
BMI (kg/m2)
 20- 25 (47%) 0.6 (0.4- 1.4) 9.6 (4.2- 17.5)
 25- 30 (38%) 1.2 (0.5- 1.6) 10.7 (7.2- 15.5)
 30+(14%) 2.2 (1.0- 4.6) .003 19.5 (11.0- 27.9) .03
Systolic blood pressure (mm Hg)
 <120 (4.1%) 0.8 (0.5- 3.3) 14.9 (7.2- 20.7)
 120- 140 (53.1%) 0.9 (0.5- 1.6) 11.5 (6.4- 17.5)
 >140 (41.8%) 1.1 (0.5- 2.0) .81 11.5 (4.3- 17.8) .52
Training last 5 days prior to the race
 0- 1 h (57%) 1.2 (0.5- 2.1)  11.8 (6.8- 19.0)
 2- 4 h (35%) 0.8 (0.4- 1.5)  12.8 (7.2- 17.5)
 More than 5 h (8%) 0.6 (0.4- 0.8) .11 3.8 (2.0- 7.0) .003
Injury during race
 Yes (9%) 0.6 (0.4- 2.4)  8.1 (3.0- 22.3)
 No (86%) 0.9 (0.5- 1.8) .91 11.7 (6.0- 17.4) .91
Medical assistance after the race
 Yes (3%) 1.4 (0.9- 1.4) 14.2 (10.3- 14.2)
 No (97%) 0.8 (0.5- 1.8) .42 11.6 (5.6- 17.5) .44
Unusual discomfort after the race
 Yes (9%) 1.0 (0.4- 1.7) 14.2 (4.0- 21.7)
 No (91%) 0.8 (0.5- 1.9) .81 11.6 (6.0- 17.4) .76
T A B L E  2  Baseline C- reactive protein 
(CRP) and CRP 24 h after the race, P values 
within subgroups, North Sea Race, Sandnes, 
Norway, June 2013
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3.3 | Predictors of CRP levels before and 
after exercise
Physical fitness assessed as race time was significantly cor-
related with baseline and 24- hour CRP levels both in uni- 
and multiple regression analysis. In contrast, among the other 
measures of physical fitness, only self- perceived physical fit-
ness level was a significant predictor of CRP levels 24 hours 
following exercise in multiple regression models. At base-
line, BMI was a significant predictor of CRP levels both in 
univariate and in multiple regression models (Table 4). BMI 
was not a predictor of CRP following physical exercise.
There was a 2.0±6.3% reduction in plasma volume follow-
ing the race. Plasma volume was calculated by the formula 
proposed by Dill and Costill.26 Plasma volume was normal-
ized 3 hour following the race. There was no correlation be-
tween plasma volume, CRP, or race time at any time- point.
3.4 | CRP levels and markers of myocardial 
damage, myocardial strain, and clinical events
There was a highly significant (P<.001) increase in cTnI (3.3 
[2.0- 4.8]- 12.7 [4.7- 24.5]) and BNP (13.7[10.0- 22.2]- 34.9[21
.0- 51.3]) immediately following physical exercise. However, 
there was no significant relationship between CRP and any of 
these markers at any time- point before or after the race. For 
the first week following the race, three participants (3.1%) 
sought medical advice due to minor infections or symptoms 
of discomfort. Nine participants (9.3%) reported unusual dis-
comfort without seeking medical attention. There was no dif-
ference in CRP levels at baseline or 24 hours following the 
race between these individuals and the rest of the participants.
4 |  DISCUSSION
This is the first study to demonstrate that high physical fit-
ness attenuates CRP increase following strenuous cycling. We 
found that high physical fitness was associated with attenuated 
basal inflammation in spite of higher training loads prior to 
CRP measurements in the most fit study participants. There 
was no relationship between CRP and markers of myocardial 
damage (cTnI), myocardial strain (BNP), or clinical events fol-
lowing strenuous physical exercise. However, following phys-
ical exercise, there was a correlation between CRP and CK 
indicating a link between muscular strain and inflammation. In 
F I G U R E  1  The figure illustrates the 
relationship between CRP levels before 
and after the race in relation to different 
measures of physical fitness and training. 
The bars represent mean (SD) CRP values 
before and after the race. CRP is assessed 
24 h prior to the race (CRP1), immediately 
following the race (CRP2), 3 h following the 
race (CRP3), and at 24 h following the race 
(CRP4). A: The relationship between CRP 
and race time divided into quartiles with Q1 
being the fastest and Q4 being the slowest. 
B: self- reported degree of fitness. C: number 
of completed endurance competitions during 
the last 5 y. D: quartiles based upon the 
number of reported training hours per week 
during the last 3 months prior to the race. 
There was a highly significant (P<.0001) 
increase between CRP1 and CRP4 in all 
groups. North Sea Race, Sandnes, Norway, 
June 2013































































Quartiles based on race time (Median and 
IQR): Q1: fastest 3.42 (3.3-3.6) h, Q4: 
slowest 5.44 (5.1-6.2) h. 
Self-reported fitness: 1: Very good (n =  8), 2: 
Good (n = 30), 3: Average (n = 37), 4: Less 
than average (n = 15), 5: Poor (n = 6).
Quartiles based on the number of completed 
endurance competitions during the past 5 
years (Median and IQR): Q1: 27.5 (20.0-
34.75) competitions, Q4: 1 (0.0-1.0) 
competitions.
Quartiles based on number of training hours 
per week (Median and IQR): Q1: 11 (9.5-
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contrast to previous publications, all relationships were inde-
pendent of age and gender. Our findings may lead us to specu-
late that the beneficial effects of high physical fitness may not 
only relate to a favorable modulation of basal inflammation 
but also an improved response to physical stress (ie, attenua-
tion of potential inappropriate inflammatory responses). This 
hypothesis has to be further investigated in a larger trial.
Our findings are supported by a recent study in 45 mar-
athon runners27 that found a correlation between race time, 
cartilage markers, and exercise- induced inflammation. Our 
study adds to this study by several findings. The strong cor-
relation between race time and baseline CRP suggests that 
race time reflects an attribute that exists prior to the compe-
tition that modulates the CRP response. We believe that race 
time in this context is a surrogate for physical fitness, under-
scoring the important role for physical fitness in the modu-
lation of the inflammatory response. Whereas the interaction 
between BMI and CRP in patients with established CVD may 
T A B L E  3  Study participants were categorized according to fitness levels based upon their race time quartiles, fastest (Q1) to slowest (Q4), 









(5.4[5.1- 6.2]) P value
Baseline characteristics
 Age (y) 40.3±9.8 44.7±11.4 44.3±7.6 41.8±9.4 .605
 Height (cm) 183.0±6.7 179.6±7.0 175.5±7.2 175.2±8.9 .001
 Female (n, %) 0(0) 5(20) 6(25) 12(50) .006
 Median heart rate during race 
(bpm)
161(151- 172) 160(151- 165) 155(144- 169) 152(144- 163) .088
 Weight (kg) 83.8±8.7 82.3±12.9 80.4±14.3 85.7±17.3 .874
 BMI (kg/m2) 25.0±2.0 25.4±3.2 25.9±3.4 27.9±5.1 .100
Training status (median (IQR))
 Years of training 5.0(3.8- 11.3) 8.0(5.0- 1.7) 6.5(3.0- 15.0) 2.5(1.0- 16.3) .030
 No of competitions/5 y 17.0(10.8- 32.8) 11.0(5.0- 19.0) 3.5(1.0- 7.3) 1.0(0.3- 4.3) <.001
 Training hours/week past 3 mo 7.5(5.0- 9.9) 6.0(3.5- 9.0) 5.25(4.3- 9.6) 5.0(3.0- 7.0) .106
 Self- reported fitness level 1.0(1.0- 1.3) 1.0(1.0- 2.0) 2.0(1.8- 2.0) 3.0 (2.0- 3.0) <.001
Biomarkers
 CRP baseline (mg/L) 0.5(0.4- 1.3) 0.6(0.4- 1.4) 1.6(0.8- 3.8) 1.3(0.5- 2.3) .004
 CRP 24 h after race (mg/L) 7.3(4.5- 9.6) 11.8(4.1- 15.7) 12.8(7.7- 21.2) 18.5(9.3- 25.0) <.001
 HbA1c (%) 5.3±0.3 5.2±0.2 5.3±0.3 5.2±0.3 .550
 Total cholesterol (mmol/L) 4.6±0.6 5.0±0.8 5.3±1.1 4.9±0.7 .077
 HDL (mmol/L) 1.5(1.3- 1.5) 1.3(1.1- 1.6) 1.3(1.0- 1.5) 1.2(1.1- 1.7) .155
 eGFR (ml/min/1.73 m2) 95.8±13.6 94.1±15.1 92.2±13.7 95.9±13.7 .758
Self- reported fitness levels: 0: best, 4: worst. North Sea Race, Sandnes, Norway, June 2013.
T A B L E  4  Multiple regression analysis (backward) at baseline and 24 h after the race using the following covariables: Age, gender, smoking 
status, HbA1c, creatine kinase (CK), body mass index (BMI), race time, number of endurance competitions over the last 5 y, number of training 
hours last 3 mo, and self- reported fitness level. North Sea Race, Sandnes, Norway, June 2013
Unstandardized coefficients Standardized coefficients
t P valueB SE Beta
CRP baseline (R2=.23)
 BMI 0.13 0.041 0.32 3.33 .001
 Race time 0.49 0.179 0.26 2.72 .008
CRP 24 h (R2=.31)
 Race time 3.28 1.25 0.29 2.63 .01
 Self- reported fitness 2.76 1.07 0.28 2.57 .012
 CK (3 h) 0.006 0.002 0.24 2.68 .009
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be rather complex,28 the additional effects of BMI on the pre-
diction of baseline CRP in the multivariable models suggest 
an additional impact of body weight, potentially as a marker 
of the long- term biological response to physical exercise.
Following physical exercise, a strong correlation between 
CRP levels and the muscle enzyme CK was found both in uni- 
and multivariable models. CK is a marker of muscular strain 
or damage that increases with muscular overload and eccentric 
work.29 Within skeletal muscle of healthy individuals, cyto-
kines such as interleukin- 6 (IL- 6) are released following phys-
ical exercise, often referred to as myokines, inducing adaptive 
responses within the muscles.30-32 IL- 6 is a major stimulant of 
CRP production in the liver, and it is possible that the increase 
in CRP observed in the present study involved release of this 
myokine.30,33 The magnitude of the CRP response appears to 
be less prominent in the present study compared with previous 
studies in marathon runners; only a ninefold in our study as 
compared with a 21- fold increase in CRP in marathon run-
ners.20,22 Interestingly, in these marathon runners, there was 
a markedly lower baseline CRP compared with our study of 
cyclists. CRP assays, blood sampling, and different study pop-
ulations may account for some of the difference. However, 
cycling is almost entirely a concentric muscular activity as 
compared to running that has a larger proportion of eccentric 
muscular work.34 In concentric muscular activity, there are 
less microruptures of the muscle fibers than in eccentric mus-
cular activity and therefore less inflammation.34-36
The present study underscores the potential beneficial ef-
fects of physical exercise on the CRP response both before 
and following physical exercise. All measures of physical 
fitness, training level, or competitive experience suggest a 
beneficial effect of increased physical activity on the inflam-
matory response. However, only measures such as race time, 
BMI, and CK remained predictors of the CRP response in 
multiple regression models. These findings suggest that it 
may be necessary to increase physical performance in order 
to improve the CRP response to stress. This finding has a po-
tentially very important implication: If a training intervention 
does not improve physical performance, improvement in the 
inflammatory response cannot be anticipated.
Elevated basal CRP levels are associated whit an increased 
risk of CV events in epidemiological studies.37,38 It is a concern 
that excessive physical activity may precipitate an adverse in-
flammatory response. In the present study, however, there was no 
evidence of a short- term deleterious effect of exercise- induced 
inflammation as suggested by a lack of a relationship between 
CRP and markers of myocardial damage, myocardial strain, or 
clinical events the first week following physical exercise.
4.1 | Limitations
The inflammatory response in the present study was modest, 
and the number of clinical events was small. Our assessment 
of the relationship between CRP and clinical endpoints 
should therefore be interpreted with caution. In order to ad-
dress the clinical consequences of the increased inflamma-
tory response, a large- scale study is warranted.
4.2 | Perspective
The present study is the first study in cyclists to demonstrate 
that physical fitness is a determinant of exercise- induced rise 
in CRP. Our findings may suggest that the beneficial effects 
of high degree of physical fitness may not only relate to a 
favorable modulation of basal inflammation but also an im-
proved biological response to physical stress.
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